Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: Release of Security Interest

CONVEYING PARTY DATA

Name	Execution Date
EOS Holdings LLC, as agent	02/17/2010

RECEIVING PARTY DATA

Name:	MDRNA, INC.
Street Address: 3830 Monte Villa Parkway	
City: Bothell	
State/Country:	WASHINGTON
Postal Code:	98021

Name:	MDRNA Research, Inc.
Street Address: 3830 Monte Villa Parkway	
City: Bothell	
State/Country:	WASHINGTON
Postal Code:	98021

Name:	Nastech Pharmaceutical Company, Inc.
Street Address: 3830 Monte Villa Parkway	
City: Bothell	
State/Country: WASHINGTON	
Postal Code:	98021

PROPERTY NUMBERS Total: 138

Property Type	Number
Patent Number:	7329725
Application Number:	60497740
Application Number:	11219625
Application Number:	12065604
Application Number:	60515533

PATENT | FEEL: 023973 FRAME: 0286

7329725

SE 5550 00

Application Number:	11955207
Application Number:	60564543
Application Number:	12013274
Application Number:	60568027
Application Number:	11223699
Application Number:	12206165
Application Number:	60570513
Application Number:	60570512
Application Number:	60613416
Application Number:	60667833
Application Number:	11576139
Application Number:	60656572
Application Number:	60720072
Application Number:	60727216
Application Number:	60733664
Application Number:	60669942
Application Number:	11910971
Application Number:	11687564
Application Number:	60774496
Application Number:	60823894
Application Number:	11627863
Application Number:	60760714
Application Number:	11623306
Application Number:	60796274
Application Number:	11610403
Application Number:	60798243
Application Number:	11743480
Application Number:	60747622
Application Number:	11750979
Application Number:	60821528
Application Number:	11774492
Application Number:	60803065
Application Number:	11676226
Application Number:	60803175
Application Number:	11676221
11	PATENT

Application Number:	60805327
Application Number:	60822896
Application Number:	60825878
Application Number:	60733665
Application Number:	60862027
Application Number:	60910393
Application Number:	60955317
Application Number:	60696136
Application Number:	60916131
Application Number:	60947282
Application Number:	60953667
Application Number:	60972653
Application Number:	12114284
Application Number:	60972590
Application Number:	60955314
Application Number:	60979772
Application Number:	12189563
Application Number:	61022571
Application Number:	60976894
Application Number:	60934940
Application Number:	60934930
Application Number:	60934931
Application Number:	12039650
Application Number:	60934928
Application Number:	60934943
Application Number:	60934934
Application Number:	60932949
Application Number:	12528508
Application Number:	60934945
Application Number:	12039658
Application Number:	60934946
Application Number:	60934935
Application Number:	60934922
Application Number:	60932970
Application Number:	12528619
	PATENT

PATENT CONTROL OF THE PATENT CONTROL OF THE

Application Number:	60956093
Application Number:	12528786
Application Number:	60973397
Application Number:	60973398
Application Number:	12039662
Application Number:	61013212
Application Number:	61013239
Application Number:	60989419
Application Number:	12529011
Application Number:	60988395
Application Number:	12529138
Application Number:	60988400
Application Number:	12529302
Application Number:	60988401
Application Number:	60988402
Application Number:	61015611
Application Number:	12529532
Application Number:	12039668
Application Number:	12552082
Application Number:	61057153
Application Number:	61220247
Application Number:	61073633
Application Number:	12486889
Application Number:	12515403
Application Number:	61086435
Application Number:	61086445
Application Number:	61106062
Application Number:	12580250
Application Number:	61116258
Application Number:	61141080
Application Number:	61119624
Application Number:	61252085
Application Number:	61145177
Application Number:	61167379
Application Number:	61258115
11	PATENT

PCT Number:	US0620627
PCT Number:	US0862526
PCT Number:	US0855615
PCT Number:	US0945664
PCT Number:	US0864417
PCT Number:	US0960930
PCT Number:	US0965153
PCT Number:	US0966610
PCT Number:	US0427806
PCT Number:	US0512653
PCT Number:	US0634859
PCT Number:	US0515574
PCT Number:	US0535259
PCT Number:	US0642978
PCT Number:	US0613374
PCT Number:	US0775744
PCT Number:	US0640174
PCT Number:	US0781836
PCT Number:	US0878627
PCT Number:	US0855380
PCT Number:	US0855360
PCT Number:	US0855385
PCT Number:	US0855339
PCT Number:	US0855515
PCT Number:	US0855644
PCT Number:	US0855649
PCT Number:	US0952878
PCT Number:	US0952888

CORRESPONDENCE DATA

Fax Number: (866)459-2899

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-326-0435

Email: john.flynn@federalresearch.com

Correspondent Name: Margaret Mitchell

Address Line 1: 7 Times Square

Address Line 2: c/o Pryor Cashman LLP

Address Line 4: New York, NEW YORK 10036 NAME OF SUBMITTER: John Flynn Total Attachments: 62 source=450877#page1.tif source=450877#page2.tif source=450877#page3.tif source=450877#page4.tif source=450877#page5.tif source=450877#page6.tif source=450877#page7.tif source=450877#page8.tif source=450877#page9.tif source=450877#page10.tif source=450877#page11.tif source=450877#page12.tif source=450877#page13.tif source=450877#page14.tif source=450877#page15.tif source=450877#page16.tif source=450877#page17.tif source=450877#page18.tif source=450877#page19.tif source=450877#page20.tif source=450877#page21.tif source=450877#page22.tif source=450877#page23.tif source=450877#page24.tif source=450877#page25.tif source=450877#page26.tif source=450877#page27.tif source=450877#page28.tif source=450877#page29.tif source=450877#page30.tif source=450877#page31.tif source=450877#page32.tif source=450877#page33.tif source=450877#page34.tif source=450877#page35.tif source=450877#page36.tif source=450877#page37.tif source=450877#page38.tif source=450877#page39.tif source=450877#page40.tif source=450877#page41.tif source=450877#page42.tif source=450877#page43.tif source=450877#page44.tif source=450877#page45.tif source=450877#page46.tif source=450877#page47.tif

source=450877#page48.tif source=450877#page49.tif



PATENT AND TRADEMARK RELEASE

WHEREAS, EOS HOLDINGS, LLC, as agent, is the secured party ("Secured Party") with respect to the patents and trademarks ("Patents and Trademarks") owned by MDRNA, INC and MDRNA RESEARCH, INC. ("Borrowers"), including, without limitation, those patents and trademarks listed on Schedule I annexed hereto and described in an Intellectual Property Security Agreement dated as of December 22, 2009 by and between Borrowers and Secured Party, notice of which was recorded with the United States Patent and Trademark Office at reels 023708 and 004121 and frames 0389 and 0896 on December 29, 2009 ("Security Agreement");

WHEREAS, Borrowers are the owners of the Patents and Trademarks; and

WHEREAS, the indebtedness secured by the Patents and Trademarks pursuant to the Security Agreement has been repaid;

NOW, THEREFORE, Secured Party, as agent for the purchasers set forth in the Note and Warrant Purchase Agreement dated December 22, 2009 by and between the Borrowers and purchasers, does hereby release any and all interests in each of Borrowers' Patents and Trademarks, including, without limitation, each patent and trademark listed on Schedule I annexed hereto.

[remainder of page intentionally left blank; signature page follows]

997719

IN WITNESS WHEREOF, Secured Party has caused this Patent and Trademark Release to be duly executed by as of the 17th day of February, 2010.

EOS Holdings, LLC

997719

ACKNOWLEDGEMENT

State of California County of Ventura

On the 17th day of February in the year 2010 before me, the undersigned, personally appeared Toseph Ramelli, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signatures(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.

Witness My Hand and Official Seal.

ROGER DUDNICK Commission # 1773346 Notary Public - California **Ventura County** Comm. Expires Nov 12, 2011

Roya Rudnis

Schedule I to Intellectual Property Security Agreement

REGISTERED COPYRIGHTS

None.

COPYRIGHT APPLICATIONS

None.

SCHEDULE 1
INTELLECTUAL PROPERTY SECURITY AGREEMENT

REEL: 023973 FRAME: 0296

Trademark Registrations/Applications

Grantor Country		Mark	Application/ Registration No.	Reg Date	
MDRNA, Inc.	US	MDRNA (Standard Characters)	77/167,387		
MDRNA, Inc.	Canada	MDRNA (Standard Characters)	1368460		
MDRNA, Inc.	India	MDRNA (Standard Characters)	1614235		
MDRNA, Inc.	Israel	MDRNA (Standard Characters)	205091		
MDRNA, Inc.	Mexico	MDRNA (Standard Characters)	891845/ 1027712	2/28/2008	
MDRNA, Inc.	New Zealand	MDRNA (Standard Characters)	778309/ 778309	4/24/2008	
MDRNA, Inc.	Madrid Protocol (EM, IS, JP, NO, KR, RU, ES, CH, UA)	MDRNA (Standard Characters)	A0010074	10/24/2007	
MDRNA, Inc.	US	MDRNA (stylized w/o color claim)	77/300,471		
MDRNA, Inc.	US	MDRNA (stylized in design w/o color claim), polymer and circle design	77/300,487 ·		
MDRNA, Inc.	Israel	MDRNA (stylized in design w/o color claim), polymer and circle design	210204		
MDRNA, Inc.	India	MDRNA (stylized in design w/o color claim), polymer and circle design	1673113		
MDRNA, Inc.	Mexico	MDRNA (stylized in design w/o color claim), polymer and circle design	924801/ 1050522	7/18/2008	
MDRNA, Inc.	Canada	MDRNA (stylized in design w/o color claim), polymer and circle design	1390066		
MDRNA, Inc.	New Zealand	MDRNA (stylized in design w/o color claim), polymer and circle design	787232		
MDRNA, Inc.	European Community	MDRNA (stylized in design w/o color claim), polymer and circle design	6857461		

ACKNOWLEDGEMENT OF GRANTOR INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE

MDRNA, Inc.	Madrid Protocol (AU, IS, JP, NO, KR, RU, ES, CH, UA)	MDRNA (stylized in design w/o color claim), polymer and circle design	A0012042/ 964650	4/10/2008
MDRNA, Inc.	US	MDRNA (stylized in design w/ color claim), polymer and circle design	77/300,514	
MDRNA, Inc.	US	(design w/o color claim) polymer design	77/300,531	

PATENT

REEL: 023973 FRAME: 0298

(certain of following trademarks may have been abandoned or transferred, or not fully prosecuted)

NPCI-0366	ILEAL B Trademark	US	73/831,647	10/16/1989	
719-20 NPCI-0367	PRO-GESIC Trademark			10/23/1989	1,635,
719-19 US	1 NO-OLOIC Hademark	US	73/833,103	10/23/1909	254
NPCI-0369	N and Design Trademark	TIC	741052 525	04/27/1990	
719-24		US	74/053,535		
NPCI-0370	NASTECH and DESIGN Trademark	US	74/062.719	05/25/1990	
719-23	<u> </u>	US	74/002,719		
NPCI-0557	METHOD FOR MAKING SELF-ASSEMBLING	US	299842	09/01/1994	55038
NPCI-0557	DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	03	299042		52
T06-01US	NASTECH PHARMACEUTICAL COMPANY INC. (in	US	78/960,995	8/25/2006	
100-0103	Design, w/ Color Claim) Trademark				
T06-02US	NASTECH PHARMACEUTICAL COMPANY INC. (in	US	78/961,002	8/25/2006	·
100-0203	Design, No Color Claim) Trademark				
T06-02CTM	NASTECH PHARMACEUTICAL COMPANY INC. and	European	6443014	11/1/2007	
	DESIGN (Black and White) Trademark	Community			<u> </u>
T06-03US	NASTECH (Stylized in Color) Trademark	US	78/962,843	8/29/2006	<u> </u>
T06-04US	NASTECH (Standard Characters) Trademark	US	78/962,854	8/29/2006	
T06-04CA	NASTECH (word only) Trademark	Canada	1378322	1/8/2008	
T06-04IL1	NASTECH (word only) Trademark	Israel	208498	2/18/2008	
T06-04IL2	NASTECH (word only) Trademark	Israel	208497	2/18/2008	
T06-04IN	NASTECH (word only) Trademark	India			
T06-04NZ	NASTECH (Standard Characters) Trademark	New Zealand	778504	10/26/2007	
T06-04MX1	NASTECH (Standard Characters) in IC 005 Trademark	Mexico	902691	12/17/2007	<u> </u>
T06-04MX2	NASTECH (Standard Characters) in IC 042 Trademark	Mexico	902696	12/17/2007	
T06-04CTM	NASTECH (Standard Characters) Trademark	European	6442991	11/1/2007	
		Community	·	•	
T06-04MP	NASTECH (standard characters) – includes European	Madrid	A0009888	10/10/2007	
	Community (EM); Iceland (IS); Japan (JP); Norway	Protocol			
	(NO); Rep. of Korea (KR); Russia (RU); Switzerland				
	(CH); Ukraine (UA) Trademark				
T06-04AU	NASTECH (standard characters) Trademark	Australia	1211348	10/10/2007	

ACKNOWLEDGEMENT OF GRANTOR INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE

APP. SERIAL

DOCKET #	FILING DATE (FD) EARLIEST PRIORITY DATE (EPD)	PRIORITY DOCUMENTS	TITLE	STATUS CATEGORY
03-10P1	U.S. 60/497,740 FD: 8/25/2003	N/A	NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND STABLE DOUBLE- STRANDED RNA	Expired CM-RC
	EPD: N/A			
03-10CIP	U.S. 11/219,625 FD: 9/2/2005 EPD: 8/25/2003	U.S. 60/497,740 U.S. 10/925,314	DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES HAVING RIBOTHYMIDINE	Pending CM-RC
	PCT/US2006/020627	U.S. 11/219,625	MODIFICATION OF DOUBLE-STRANDED	National
03-10CIP- PCT	FD: 5/25/2006	U.S. 11/219,582 U.S. 60/720,072 U.S. 11/361,793	RIBONUCLEIC ACID MOLECULES	Stage Entry
	EPD: 9/2/2005	U.S. 60/796,274		CM-RC
03-10PCT	PCT/US2004/027806 FD: 8/25/2003	U.S. 60/497,740	NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND STABLE DOUBLE-STRANDED RNA	National Stage Entry
	EPD: 8/25/2003			D
	U.S. 12/065,604		MODIFICATION OF DOUBLE-STRANDED	
03-10US2	FD: 3/3/2008	U.S. 60/720,072 PCT/US2006/020627	RIBONUCLEIC ACID MOLECULES	Pending CM-RC
	EPD: 9/23/2005			
	U.S. 60/515,533		PHAGE DISPLAY TRP CAGE LIGANDS	
03-12P1	FD: 10/29/2003	N/A		Expired D
	EPD: N/A			
	U.S. 11/955,207		PHAGE DISPLAYED TRP CAGE LIGANDS	
03-12CON	FD: 12/12/2007	U.S. 60/515,533 U.S. 7,329,725		Pending D
	EPD: 10/29/2003			
	U.S. 7,329,725		PHAGE DISPLAYED TRP CAGE LIGANDS	
03-12US	FD: 10/29/2004	U.S. 60/515,533		Issued D
	EPD: 10/29/2003			
	U.S. 60/564,543		CONJUGATION OF A CHOLESTEROL MOIETY	
04-02P1	FD: 4/20/2004	N/A	TO DOUBLE-STRANDED RNA OR A DOUBLE- STRANDED HYBRID NUCLEIC ACID	Expired D
	EPD: N/A			

ACKNOWLEDGEMENT OF GRANTOR INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE

	U.S. 12/013,274		METHODS AND COMPOSITIONS FOR	
04 000001	777 1/11/0000	U.S. 11/107,371	ENHANCING DELIVERY OF DOUBLE-	Pending
04-02CON	FD: 1/11/2008	U.S. 60/564,543	STRANDED RNA OR A DOUBLE-STRANDED	
	EDD: 4/20/2004		HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS	D
	EPD: 4/20/2004 PCT/US2005/012653		METHODS AND COMPOSITIONS FOR	National
}	PC1/U32003/012033		ENHANCING DELIVERY OF DOUBLE-	Stage
04-02PCT	FD: 4/15/2005	U.S. 60/564,543	STRANDED RNA OR A DOUBLE-STRANDED	Entry
04-02FC1	FD. 4/13/2003	0.5.00/504,545	HYBRID NUCLEIC ACID TO REGULATE GENE	Linuy
	EPD: 4/20/2004		EXPRESSION IN MAMMALIAN CELLS	D
	U.S. 60/568,027		HISTONES COMPLEXED OR COVALENTLY	
	• · · · · · · · · · · · · · · · · · · ·		BONDED TO DOUBLE-	Expired
04-03P1	FD: 5/4/2004	N/A	STRANDED RNA OR TO AN RNA/DNA HYBRID	-
				D
	EPD: N/A			
		U.S. 11/121,566	PHARMACEUTICAL COMPOSITIONS FOR	
	U.S. 11/223,699	U.S. 60/667,833	DELIVERY OF RIBONUCLEIC ACID TO A CELL	
	TTD 040/2007	U.S. 60/565,572		Pending
04-03CIP	FD: 9/8/2005	U.S. 60/613,416		
	EDD 51410004	U.S. 60/570,513		D
	EPD: 5/4/2004	U.S. 60/570,512		
		U.S. 60/568,027	· ·	
	PCT/US2006/034859		PHARMACEUTICAL COMPOSITIONS FOR	National
0.4.00.077		U.S. 60/733,664	DELIVERY OF RIBONUCLEIC ACID TO A CELL	Stage
04-03CIP-	FD: 9/8/2006	U.S. 60/727,216		Entry
PCT		U.S. 11/223,699		-
	EPD: 9/8/2005			D
	PCT/US2005/015574	U.S. 60/568,027	COMPOSITIONS AND METHODS FOR	
:	101,052005,015571	U.S. 60/570,512	ENHANCING DELIVERY OF NUCLEIC ACIDS	National
0.4.00DGTT	FD: 5/4/2005	U.S. 60/570,513	INTO CELLS AND FOR MODIFYING	Stage
04-03PCT	:	U.S. 60/613,416	EXPRESSION OF TARGET GENES IN CELLS	Entry
	EPD: 5/4/2004	U.S. 60/656,572		D
		U.S. 60/667,833		D
		U.S. 11/121,566	COMPOSITIONS AND METHODS FOR	
,	U.S. 12/206,165	U.S. 60/667,833	ENHANCING DELIVERY OF NUCLEIC ACIDS	
		U.S. 60/565,572	INTO CELLS AND FOR MODIFYING	Pending
04-03CON	FD: 9/8/2008	U.S. 60/613,416	EXPRESSION OF TARGET GENES IN CELLS	1 chang
04-030011		U.S. 60/570,513		D
	EPD: 5/4/2004	U.S. 60/570,512		ب
		U.S. 60/568,027		
	U.S. 60/570,513		POLYPEPTIDES COMPLEXED OR COVALENLTY	
	0.0.00/0/0,515		BONDED TO DOUBLE-STRANDED RNA OR	Expired
04-05P1	FD: 5/12/2004	N/A	RNA/DNA HYBRID	~p.1.00
0.0511		- 17	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	D
	EPD: N/A			_
	U.S. 60/570,512		POLYPEPTIDES COMPLEXED OR LINKED TO	
	/-		DOUBLE-STRANDED RNA OR TO AN RNA/DNA	Expired
04-06P1	FD: 5/12/2004	N/A	HYBRIDE WITH A CATIONIC LIPID	•
				D
	EPD: N/A			

	EPD: 11/4/2005			D
05-20PCT	FD: 11/3/2006	U.S. 60/733,665	AS DELIVERY VEHICLES FOR SIRNA	Stage Entry
	EPD: N/A PCT/US2006/042978		PEPTIDE-DICER SUBSTRATE RNA CONJUGATES	National
05-20P1	FD: 11/4/2005	N/A	AS DELIVERY VEHICLES FOR SIRNA	Expired D
	EPD: N/A U.S. 60/733,665		PEPTIDE-DICER SUBSTRATE RNA CONJUGATES	
05-17P1	FD: 11/4/2005	N/A	DOUBLE STRANDED RNA	Expired D
	U.S. 60/733,664		PEPTIDE MEDIATED CELLULAR UPTAKE OF	
	EPD: N/A			D
05-16P1	U.S. 60/727,216 FD: 10/14/2005	N/A	PEPTIDE-MEDIATED SIRNA UPTAKE INTO CELLS	Expired
	EPD: N/A		DEDTINE MENTATED GIDALA TIDILATE INTO	CIVI-RC
05-13P1	FD: 9/23/2005	N/A	RIBONUCLEIC AICDS AND PEPTIDES	Expired CM-RC
	U.S. 60/720,072		CHEMICALLY MODIFIED DOUBLE-STRANDED	
05-01P1	FD: 2/25/2005 EPD: N/A	N/A	FUSOGENIC POLYPEPTIDE TO A SMALL INTERFERING NUCLEIC ACID FOR FOR USE IN RNA INTERFERENCE	D
	U.S. 60/656,572		CONJUGATION OR COMPLEXATION OF A PROTEIN TRANDUCTION DOMAIN AND	Expired
	EPD: 9/27/2004	U.S. 60/656,572 U.S. 60/613,416	·	GF-TI
04-17US	FD: 3/27/2007	U.S. 11/223,699 U.S. 11/121,566 U.S. 60/667,833	DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID	Pending
	U.S. 11/576,139	PCT/US2005/035259	METHOD OF TREATING AN INFLAMMATORY	Gr-11
04-17PCT	FD: 9/27/2005 EPD: 9/27/2004	U.S. 60/667,833 U.S. 60/656,572 U.S. 60/613,416	RIBONUCLEIC ACID	Entry GF-TI
	PCT/US2005/035259	U.S. 11/121,566	METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED	National Stage
	EPD: N/A			GF-TI
04-17P2	FD: 4/1/2005	N/A	INTERFERENCE TO TREAT RHEUMATOID ARTHRITIS	Expired
	EPD: N/A U.S. 60/667,833		COMPOSITIONS AND METHODS FOR RNA	
4-17P1	FD: 9/27/2004	N/A	MILOMITOD /MIMMIS	GF-TI
	U.S. 60/613,416		THE USE OF RNA INTERFERENCE TO TREAT RHEUMATOID ARTHRITIS	Expired

		T	T	· · · · · · · · · · · · · · · · · · ·
	U.S. 60/669,942		ANTI-VIRAL COMPOSITIONS AND METHODS OF	T1
05-25P1	ED- 4/9/2005	N/A	USE THEREOF	Expired
U3-23P1	FD: 4/8/2005	IV/A		GF-TI
	EPD: N/A			G1-11
	U.S. 11/910,971		RNAI THERAPEUTIC FOR RESPIRATORY VIRUS	
		PCT/US2006/013374	INFECTION	Pending
05-25US	FD: 10/8/2007	U.S. 60/669,942		
		0.5. 00/000,542	·	GF-TI
	EPD: 4/8/2005	· · · · · · · · · · · · · · · · · · ·	DALLE HELICA DE DESCRIPTO DE LA MODELLA MODELL	
	U.S. 11/687,564	•	RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION	Pending
05-25CIP	FD: 3/16/2007	PCT/US2006/013374	INFECTION	rending
05-25CH	10.5/10/2007	U.S. 60/669,942		GF-TI
	EPD: 4/8/2005			
	U.S. 60/774,496		PHAGE DISPLAYED CELL BINDING PEPTIDES	
				Expired
06-02P1	FD: 2/17/2006	N/A		_
	EPD: N/A			D
	U.S. 60/823,894		PHAGE DISPLAYED CELL BINDING PEPTIDES	
	0.3. 00/023,094		THAGE DISTERTED CELE DINDING TELTIDES	Expired
06-02P2	FD: 8/29/2006	N/A	·	
				D
	EPD: N/A			
]	U.S. 11/627,863		PHAGE DISPLAYED CELL BINDING PEPTIDES	
04 00770	ED. 1/0//0007	U.S. 60/823,894	·	Pending
06-02US	FD: 1/26/2007	U.S. 60/774,496		D
	EPD: 2/17/2006			, D
	PCT/US2006/013374		RNAI THERAPEUTIC FOR RESPIRATORY VIRUS	National
			INFECTION	Stage
05-25PCT	FD: 4/7/2006	U.S. 60/669,942		Entry
	EPD: 4/8/2005		DRY POWDER COMPOSITIONS	GF-TI
	U.S. 60/760,714		DRI POWDER COMPOSITIONS	Expired
06-11P1	FD: 1/20/2006	N/A		Expired
	12111201200			GF-TI
	EPD: N/A			
	U.S. 11/623,306		DRY POWDER COMPOSITIONS FOR RNA	
	111 110 000	11.0 (0.000.001)	INFLUENZA THERAPEUTICS	Pending
06-11US	FD: 1/15/2007	U.S. 60/760,714		Cir. ant
	EPD: 1/20/2006			GF-TI
	U.S. 60/796,274		COMPOSITIONS AND METHODS EMPLOYING	
			UNIVERSAL-BINDING NUCLEOTIDES FOR	Expired
06-14P1	FD: 4/27/2006	N/A	TARGETING MULTIPLE GENE VARIANTS WITH	•
			A SINGLE siRNA DUPLEX	CM-RC
	EPD: N/A			·
	U.S. 11/610,403		COMPOSITIONS AND METHODS EMPLOYING	D31
06 14119	FD: 12/13/2006	U.S. 60/796,274	UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH	Pending
06-14US	FD: 12/13/2000	0.3. 00/790,274	A SINGLE SIRNA DUPLEX	CM-RC
	EPD: 4/27/2006		11 OH OLL SIGHA DOLLEA	CIVI-ICC
			<u> </u>	

	U.S. 60/798,243	·	COMPOSITIONS AND METHODS FOR LIPID AND	
	0.3.00/198,243		POLYPEPTIDE BASED siRNA INTRACELLULAR	Expired
06-16P1	FD: 5/5/2006	N/A	DELIVERY	Expired
				D
	EPD: N/A			·
	U.S. 11/743,480		COMPOSITIONS AND METHODS FOR LIPID AND	
06 16110	ED 5/0/0007	U.S. 60/798,243	POLYPEPTIDE BASED SIRNA INTRACELLULAR	Pending
06-16US	FD: 5/2/2007	,	DELIVERY	D
	EPD: 5/5/2006			D.
	U.S. 60/747,622	<u> </u>	FORMULATIONS FOR INTRACELLULAR	
			DELIVERY dsRNA	Expired
06-17P1	FD: 5/18/2006	N/A		
	EDD 37/4		·	D
	EPD: N/A U.S. 11/750,979		FORMULATIONS FOR INTRACELLULAR	
	0.3. 11/730,979	•	DELIVERY dsRNA	Pending
06-17US	FD: 5/18/2007	U.S. 60/747,622	DILLIVERT GSRIVE	1 chaing
	22.0.10.200			D
	EPD: 5/18/2006			
	U.S. 60/821,528		DEVICE FOR IMPROVED PEPTIDE DELIVERY	
06 1001	FD- 9/4/0006	N/A		Expired
06-18P1	FD: 8/4/2006	IN/A		D
	EPD: N/A			Ъ
	U.S. 11/774,492		DEVICE FOR IMPROVED PEPTIDE DELIVERY	
		U.S. 60/821,528		Pending
.06-18US	FD: 7/6/2007	0.5. 00/021,520		
	EDD: 0/4/2006			D
	EPD: 8/4/2006 U.S. 60/803,065		COMPOSITIONS AND METHODS FOR	
	0.3. 00/803,003		COMPLEXES OF NUCLEIC ACIDS AND	Expired
06-20P1	FD: 5/24/2006	N/A	ORGANIC CATIONS	p
			·	SF-MPC
	EPD: N/A			
	U.S. 11/676,226		COMPOSITIONS AND METHODS FOR	D 1:
06-20US	FD: 2/16/2007	U.S. 60/803,065	COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS	Pending
00-2003	FD. 2/10/2007	•	ONGAINE CATIONS	SF-MPC
	EPD: 5/24/2006			52 1112 C
	U.S. 60/803,175		CATIONIC PEPTIDES FOR siRNA	
			INTRACELLULAR DELIVERY	Expired
06-21P1	FD: 5/25/2006	N/A		ъ
	EPD: N/A			. D
	U.S. 11/676,221		CATIONIC PEPTIDES FOR siRNA	
			INTRACELLULAR DELIVERY	Pending
06-21US	FD: 2/16/2007	U.S. 60/803,175	·	J
_				D
	EPD: 5/25/2006		COMPOSITIONS AND MERITORS FOR LIDE	
	U.S. 60/805,327		COMPOSITIONS AND METHODS FOR LIPID- BASED SIRNA	Expired
06-22P1	FD: 6/20/2006	N/A	INTRACELLULAR DELIVERY	Expired
00 2211	1 D. GIDGIDGO			D
	EPD: N/A			

	TT C (0/011 004	<u> </u>	PEPTIDE-DICER SUBSTRATE RNA CONJUGATES	
	U.S. 60/822,896	•	AS DELIVERY VEHICLES FOR SIRNA	Expired
06-31P1	FD: 8/18/2006	N/A	AS DELIVERT VEHICLES FOR SIRINA	Expired
00-3111	1.0.0/10/2000	IVA		D
	EPD: N/A		•	
	PCT/US2007/075744		DICER SUBSTRATE RNA PEPTIDE CONJUGATES	
		U.S. 60/945,868	AND METHODS FOR RNA THERAPEUTICS	Pending
06-31PCT	FD: 8/10/2007	U.S. 60/939,578		
		U.S. 60/822,896		D
	EPD: 8/18/2006			
	U.S. 60/825,878		COMPOUNDS AND METHODS FOR PEPTIDE	
06 2201	ED. 0/15/0006	DT/A	RIBONUCLEIC ACID	Expired
06-32P1	FD: 9/15/2006	N/A	CONDENSATE PARTICLES FOR RNA THERAPEUTICS	D
	EPD: N/A		THERAPEUTICS	ע
	PCT/US2006/040174		COMPOUNDS AND METHODS FOR PEPTIDE	
	2 02, 002000, 0, 02, 1	U.S. 60/825,878	RIBONUCLEIC ACID	National Stage
06-32PCT	FD: 10/13/2006	U.S. 60/733,665	CONDENSATE PARTICLES FOR RNA	Entry
		U.S. 60/727,216	THERAPEUTICS	D
	EPD: 9/15/2006			Б
	U.S. 60/862,027		COMPOSITIONS AND METHODS EMPLOYING	
0<0484	TT 10/10/0006	****	GAPPED OR NICKED SIRNA MOLECULES	Expired
06-34P1	FD: 10/18/2006	N/A		CM DC
	EPD: N/A			CM-RC
	U.S. 60/910,393		COMPOSITIONS AND METHODS OF USING	
	0.5. 00//10,5/5		GAPPED OR NICKED DOUBLE STRANDED	Expired
07-04P2	FD: 4/5/2007	N/A	NUCLEIC ACID MOLECULES	2.151100
				CM-RC
	EPD: N/A			
	U.S. 60/955,317		COMPOSITIONS AND METHODS OF USING	
07.0470	777 041010007	27/4	DOUBLE-STRANDED NUCLEIC ACID	Expired
07-04P3	FD: 8/10/2007	N/A	MOLECULES CONTAINING ONE OR MORE GAP	CM DC
	EPD: N/A		OR NICK	CM-RC
	U.S. 60/969,136		COMPOSITIONS AND METHODS OF USING	
:	0.5. 00/707,150		DOUBLE-STRANDED NUCLEIC ACID	Expired
07-04P4	FD: 8/30/2007	N/A	MOLECULES CONTAINING ONE OR MORE GAP	
			OR NICK	CM-RC
	EPD: N/A			
			NICKED OR GAPPED NUCLEIC ACID	
	PCT/US2007/081836	***	MOLECULES AND USES THEREOF	
	TT 10/10/2007	U.S. 60/969,136		National Stage
07-04PCT	FD: 10/18/2007	U.S. 60/955,317		Entry
] · · [EPD: 10/18/2006	U.S. 60/910,393 U.S. 60/862,027		CM-RC
	1117. 10/10/2000	0.5. 00/002,02/		CIVI-RC
	U.S. 60/916,131		AMINO ACID LIPID COMPOSITIONS AND	
	· .		METHODS FOR DELIVERING RNA	Expired
07-10P1	FD: 5/4/2007	N/A	THERAPEUTICS	_
		•		D
	EPD: N/A			

	U.S. 60/947,282		AMINO ACID LIPID COMPOSITIONS AND	
	0.0. 00,7 17,202		METHODS FOR DELIVERING RNA	Expired
07-10P2	FD: 6/29/2007	N/A	THERAPEUTICS	1
				D
	EPD: N/A		ANTINO A OTTO I YOUR CONTROLLY AND	
	U.S. 60/953,667		AMINO ACID LIPID COMPOSITIONS AND METHODS FOR DELIVERING RNA	Expired
07-10P3	FD: 8/2/2007	N/A	THERAPEUTICS	Expired
0, 1015	10.0/2/2007	1777	TIBERT BOTTOS	D
	EPD: N/A		·	
	U.S. 60/972,653		AMINO ACID LIPIDS AND USES FOR RNA	
07.1004	ED. 0/14/0007	BT/A	THERAPEUTICS	Expired
07-10P4	FD: 9/14/2007	N/A		D
	EPD: N/A		•	
	PCT/US2008/62526	U.S. 60/972,653	AMINO ACID LIPIDS AND USES THEREOF	NT-411 G4
		U.S. 60/953,667		National Stage Entry
07-10PCT	FD: 5/2/200	U.S. 60/947,282		Linuy
	EDD. 514/2007	U.S. 60/916,131		D
	EPD: 5/4/2007 U.S. 12/114,284	U.S. 60/972,653	AMINO ACID LIPIDS AND USES THEREOF	
	O.B. 12/114,204	U.S. 60/953,667	AWING ACID BILLDS AND COLS TILEARD	Pending
07-10US	FD: 5/2/200	U.S. 60/947,282		
	,	U.S. 60/916,131		D
	EPD: 5/4/2007			
	U.S. 60/972,590		EMULSION COMPOSITIONS FOR INTERFERING	17
07-15P1	FD: 9/14/2007	N/A	RNA AND USES THEREOF	Expired
07 151 1	12. 7/14/2007			D
	EPD: N/A	•		
	U.S. 60/955,314		RNA THERAPEUTICS FOR DRUG RESISTANT	
07-17P1	FD: 8/10/2007	N/A	INFLUENZA	Expired
07-17P1	FD: 8/10/2007	IN/A		GF-TI
	EPD: N/A			0
	U.S. 60/979,772		USES OF BROAD SPECTRUM RNAI	
			THERAPEUTICS AGAINST INFLUENZA	Pending
07-17 P 2	FD: 10/12/2007	N/A	·	CD TI
j l	EPD: N/A			GF-TI
	U.S. 12/189,563		USES OF BROAD SPECTRUM RNAI	
		U.S. 60/979,772	THERAPEUTICS AGAINST INFLUENZA	Pending
07-17US	FD: 8/11/2008	U.S. 60/955,314		
	EDD. 9/10/2007			GF-TI
ļ	EPD: 8/10/2007 U.S. 61/022,571		DISPERSION COMPOSITIONS FOR INTERFERING	
	U.U. UI/U <i>LL</i> ,J/1		RNA AND USES THEREOF	Pending
07-21P1	FD: 1/22/2008	N/A		
				D
	EPD: N/A		I IDODEDNE DE CON DEL MISTO CON DIVIDIO	
	U.S. 60/976,894		LIPOPEPTIDES FOR DELIVERY OF INTERFERING RNA AGENTS	Evnical
07-23P1	FD: 10/2/2007	N/A	MIA VOENTO	Expired
0, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	12.10.2.2001	2722	· ·	D
	EPD: N/A			

	PCT/US2008/078627		LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS	Pending
07-23PCT	FD: 10/2/2008	U.S. 60/976,894	ACIDS	_
	EPD: 10/2/2007		•	D
	U.S. 60/934,940	······································	COMPOUNDS FOR INHIBITING TNF GENE	
07-R001P1	FD: 3/2/2007	N/A	EXPRESSION BY RIBONUCLEIC ACID INTERFERENCE AND USES THEROF	Abandoned
	EPD: N/A			GF-TI
	U.S. 60/934,930		COMPOUNDS FOR INHIBITING GENE	17
07-R002P1	FD: 3/16/2007	N/A	EXPRESSION BY RIBONUCLEIC ACID INTERFERENCE AND USES THEREOF	Expired GF-TI
	EPD: N/A			GI-II
	U.S. 60/934,931		NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF	Expired
07-R004P1	FD: 4/20/2007	N/A		CID III
	EPD: N/A		·	GF-TI
07- R004US	U.S. 12/039,650 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,931 U.S. 60/934,934 U.S. 60/934,943 U.S. 60/934,943 U.S. 60/934,942	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF	Pending GF-TI
	U.S. 60/934,928		NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGFB GENE EXPRESSION AND USES	Expired
07-R007P1	FD: 4/24/2007	N/A	THEREOF	-
Ì	EPD: N/A			GF-TI
	U.S. 60/934,943		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-R009P1	FD: 4/25/2007	N/A	FIGF GENE EXPRESSION AND USES THEREOF	Expired GF-TI
	EPD: N/A			Gr-11
	U.S. 60/934,934		NUCLEIC ACID COMPOUNDS FOR INHIBITING PGF GENE EXPRESSION AND USES THEREOF	
07-R010P1	FD: 4/24/2007	N/A		Expired
	EPD: N/A			GF-TI

	EPD: N/A			
07-R015P1	FD:5/15/2007	N/A	ERBB3 GENE EXPRESSIONAND USES THEREOF	Expired GF-TI
	EPD: N/A U.S. 60/934,935		NUCLEIC ACID COMPOUNDS FOR INHIBITING	· · · · · · · · · · · · · · · · · · ·
07-R014P1	FD:5/03/2007	N/A	ERBB2 GENE EXPRESSIONAND USES THEREOF	Expired GF-TI
	U.S. 60/934,946		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
		U.S. 60/934,922	•	
R013US	EPD: 3/2/2007	U.S. 60/934,945 U.S. 60/934,935		GF-TI
07-	FD: 2/28/2008	U.S. 60/934,930 U.S. 60/934,946		Pending
	U.S. 12/039,658	U.S. 60/934,940	ERBB GENE EXPRESSIONAND USES THEREOF	
	EPD: N/A		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-R013P1	FD:5/10/2007	N/A	EGIA GENE EXTRESSION AND USES TREKEUP	Expired GF-TI
	U.S. 60/934,945		NUCLEIC ACID COMPOUNDS FOR INHIBITING EGFR GENE EXPRESSION AND USES THEREOF	Typicad
	DI D. 31414001	PCT/US2008/055380		
R011US	EPD: 3/2/2007	U.S. 60/934,934 U.S. 60/934,928		GF-TI
07-	FD: 2/28/2008	U.S. 60/934,930 U.S. 60/934,931		Pending
	U.S. 12/528,508	U.S. 60/934,940	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF	
R011PCT	EPD: 3/2/2007	U.S. 60/934,943 U.S. 60/932,949		GF-TI
07-	FD: 2/28/2008	U.S. 60/934,934 U.S. 60/934,928		Stage Entry
	PCT/US2008/055380	U.S. 60/934,930 U.S. 60/934,931	THEREOF	National
		U.S. 60/934,940	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES	
	EPD: N/A			GF-11
07-R011P1	FD:5/03/2007	N/A		Expired GF-TI
	U.S. 60/932,949		NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF	Turning

	U.S. 60/934,922		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
			ERBB4 GENE EXPRESSIONAND USES THEREOF	Expired
07-R016P1	FD:5/17/2007	N/A		CETI
	EPD: N/A			GF-TI
	U.S. 60/932,970		NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES	
07-R017P1	FD:5/22/2007	N/A	THEREOF	Expired
	EPD: N/A			GF-TI
07- R017PCT	PCT/US2008/055360 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,946 U.S. 60/934,945 U.S. 60/934,935 U.S. 60/934,922 U.S. 60/932,970	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07- R017US	U.S. 12/528,619 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,946 U.S. 60/934,945 U.S. 60/934,935 U.S. 60/934,922 U.S. 60/932,970 PCT/US2008/055360	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R037P1	U.S. 60/956,093 FD:8/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07- R037PCT	PCT/US2008/055385 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/956,093	NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI

	T	The state of the s	TATION THE LOTE CONTROL TO THE PROPERTY OF THE	
			NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	U.S. 12/528,786		HIF1A GENE EXPRESSION AND USES THEREOF	
	0.3. 12/326,760	U.S. 60/934,940		
07-	FD: 2/28/2008	U.S. 60/934,930		Pending
	FD: 2/26/2006		·	_
R037US	EDD 0/0/0002	U.S. 60/956,093		GF-TI
	EPD: 3/2/2007	PCT/US2008/055385		
	U.S. 60/973,397		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
,	0.3. 00/9/3,39/		RAF1 GENE EXPRESSION AND USES THEREOF	177i d
07 D044D1	FD:9/18/2007	N/A	RAFI GENE EXPRESSION AND USES THEREOF	Expired
07-R044P1	FD:9/18/2007	IN/A		· OF THE
	EDD. MA			GF-TI
	EPD: N/A		NHIGH FIG. 4 GIP. GOV POLITING FOR THE PROPERTY OF	
	U.S. 60/973,398		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
		27/4	AKT1 GENE EXPRESSION AND USES THEREOF	Expired
07-R045P1	FD:9/18/2007	N/A	·	
				GF-TI
	EPD: N/A			
			NUCLEIC ACID COMPOUNDS FOR INHIBITING	
			AKT GENE EXPRESSION AND USES THEREOF	
		U.S. 60/934,940		
	PCT/US2008/055339	U.S. 60/934,930		
		U.S. 60/973,398		National
07-	FD: 2/28/2008	U.S. 60/013,212		Stage
R045PCT	*	U.S. 60/013,239		Entry
10451 61	EPD: 3/2/2007	U.S. 60/973,397	·	
	El D. 3/2/2007	0.0.00773,377		GF-TI
'				
		·	·	
			ATTOLETA TOD COT WOLDING BOD BITTING AND	, "
			NUCLEIC ACID COMPOUNDS FOR INHIBITING	
			AKT GENE EXPRESSION AND USES THEREOF	
			·	
	U.S. 12/039,662	U.S. 60/934,940		
		U.S. 60/934,930		Pending
07-	FD: 2/28/2008	U.S. 60/973,398		rending
R045US		U.S. 60/013,212		CIE TET
[EPD: 3/2/2007	U.S. 60/013,239		GF-TI
.		U.S. 60/973,397		
			· ·	
		·		
		-	NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	U.S. 61/013,212		AKT2 GENE EXPRESSION AND USES THEREOF	
.	,		AK12 OBIGE EAL RESSION AND USES THEREOF	
	FD:12/12/2007			Expired
07-R046P1		N/A		
	EPD: N/A			GF-TI
			•	

	TI C 61/012 220	T	NUCLEIC ACID COMPOUNDS FOR INTURITING	
<u> </u>	U.S. 61/013,239		NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT3 GENE EXPRESSION AND USES THEREOF	Expired
07-R047P1	FD:12/12/2007	N/A	ARTS GENE EXPRESSION AND USES THEREOF	GF-TI
	EPD: N/A			. 01-11
	U.S. 60/989,419		NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	
07-R060P1	FD:11/20/2007	N/A		Expired
	EPD: N/A			GF-TI
	PCT/US2008/055515		NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	National
07- R060PCT	FD: 2/29/2008	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/989,419		Stage Entry
ROOOLCI	EPD: 3/2/2007	0.3. 00/707,417		GF-TI
	U.S. 12/529,011	U.S. 60/934,940	NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	
07	FD: 2/29/2008	U.S. 60/934,930 U.S. 60/989,419 PCT/US2008/055515		Pending
07- R060US	EPD: 3/2/2007			GF-TI
			:	
	U.S. 60/988,395		NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF	Expired
07-R071P1	FD:11/15/2007	N/A		-
	EPD: N/A		·	GF-TI
		,	NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	PCT/US2008/55615	U.S. 60/934,940	MYC GENE EXPRESSION AND USES THEREOF	National
07-	FD: 3/3/2008	U.S. 60/934,930		Stage Entry
R071PCT	EPD: 3/2/2007	U.S. 60/988,395		-
	D. D. 31212001		·	GF-TI
			NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	U.S. 12/529,138	U.S. 60/934,940 U.S. 60/934,930	MYC GENE EXPRESSION AND USES THEREOF	
07-	FD: 3/3/2008	U.S. 60/988,395		Pending
R071US	EPD: 3/2/2007	PCT/US2008/55615		GF-TI
	EFD: 3/2/2007			

	U.S. 60/988,400		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-R075P1	FD:11/15/2007	N/A	NRAS GENE EXPRESSION AND USES THEREOF	Expired
0, 10,511				GF-TI
	EPD: N/A		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
			RAS GENE EXPRESSION AND USES THEREOF	
07- R075PCT	PCT/US2008/055644 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/988,400 U.S. 60/988,401 U.S. 60/988,402		National Stage Entry GF-TI
			NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF	
	U.S. 12/529,302	U.S. 60/934,940 U.S. 60/934,930		
07-	FD: 3/3/2008	U.S. 60/988,400	·	Pending
R075US		U.S. 60/988,401 PCT/US2008/055644		GF-TI
	EPD: 3/2/2007			
	U.S. 60/988,401		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-R076P1	FD:11/15/2007	N/A	HRAS GENE EXPRESSION AND USES THEREOF	Expired
				GF-TI
	EPD: N/A		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	U.S. 60/988,402		KRAS GENE EXPRESSION AND USES THEREOF	.
07-R077P1	FD:11/15/2007	N/A	·	Expired
	EPD: N/A		·	GF-TI
	U.S. 61/015,611		NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT3A GENE EXPRESSION AND USES	Expired
07-R079P1	FD:12/20/2007	N/A	THEREOF	_
	EPD: N/A			GF-TI
	PCT/US2008/055649		NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF	
07		U.S. 60/934,940	WINT GEINE EAFRESSION AIND USES THEREOF	National Stage
07- R079PCT	FD: 3/3/2008	U.S. 60/934,930 U.S. 61/015,611		Entry
	EPD: 3/2/2007			GF-TI
				•

· ·	U.S. 12/529,532	U.S. 60/934,940	NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-	0.5. 12/527,552	U.S. 60/934,930	WNT GENE EXPRESSION AND USES THEREOF	Pending
R079US	FD: 3/3/2008	U.S. 61/015,611		_
10,700	EPD: 3/2/2007	PCT/US2008/055649		GF-TI
	٠.		NUCLEIC ACID COMPOUNDS FOR INHIBITING	
	U.S. 12/039,668	U.S. 60/934,940	APOB GENE EXPRESSION AND USES THEREOF	
07-	FD: 2/28/2008	U.S. 60/934,940 U.S. 60/934,930		Pending
R107US		U.S. 60/992,975		GF-TI
	EPD: 3/2/2007		·	GI-II
	U.S. 12/552,082	50 D.C	NUCLEIC ACID COMPOUNDS FOR INHIBITING	
07-R-US-	·	79 PCT Patent Applications	GENE EXPRESSION AND USES THEREOF	Pending
CIP	FD: 09/02/2009	Covering over 140		CIC TIT
	EPD: 3/2/2007	Gene Targets		GF-TI
			LIPOPHILIC AMINES AND USES THEREOF	
	U.S. 61/057,153		En Officie Amines And Oses Thereof	
	· ·			Expired
08-01P1	FD: 5/29/2008	N/A		
2	EPD: N/A			D
	212.17,11			
			MULTI-ARM AMINES AND USES THEREOF	
	PCT/US2009/45664			
08-01PCT	FD: 5/29/2009	U.S. 61/057,153	;	Pending
00-011 C1	1 D. 3/2//2007	0.6.01/05/,155		D
	EPD: 5/29/2008			
	TI G (1/000 047)		DECLINATION AND LIGHT	
	U.S. 61/220,247		REGULATORY NUCLEIC ACIDS AND USES THEREOF	Pending
08-04P2	FD:6/25/2009	N/A		-
	EDD. M/A			CM-RC
	EPD: N/A U.S. 61/073,633		RIBONUCLEIC ACIDS WITH NON-STANDARD	
			BASES AND USES THEREOF	Pending
08-06P1	FD:6/18/2008	N/A		CM DC
	EPD: N/A			CM-RC
	U.S. 12/486,889		RIBONUCLEIC ACIDS WITH NON-STANDARD	
00 00110	ED.6/19/0000	U.S. 61/073,633	BASES AND USES THEREOF	Pending
08-06US	FD:6/18/2009			СН
	EPD: 6/18/2008		, :	
	PCT/US2008/64417	PA 200800534	HYDROXYMETHYL SUBSTITUTED RNA	D 7
08-07PCT	FD: 5/21/2008	PA 200701785	OLIGONUCLEOTIDES AND RNA COMPLEXES	Pending
00 0/101	12,5,2,2000	PA 200701718 PA 200700751		CM-RC
	EPD: 5/22/2007	IA 200/00/31		

PA 200800534 PA 200701718 PA 200700751 U.S. 61/086,435 PA 200700751 U.S. 61/086,435 NI/A EPD: N/A PCT/US2009/052878 U.S. 61/086,435 U.S. 61/086,435 PCT/US2009/052878 U.S. 61/086,435 Pendir EXPRESSION AND USES THEREOF Pendir DELIVERY OF GENE EXPRESSION AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pendir DELIVERY OF GENE EXPRESSION AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pendir DELIVERY OF TRIGGERED RELEASE THERAP		U.S. 12/515,403	PCT/US2008/64417	HYDROXYMETHYL SUBSTITUTED RNA	
08-07US		0.5. 12,515,105	1	1	Pending
PED: 5/22/2007	08-07US	FD: 5/21/2008	ľ		-
U.S. 61/086,435 FD:8/5/2008 N/A EPD: N/A EPD: N/A PCT/US2009/052878 TD:8/5/2008 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,435 EPD: 08/05/2008 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,435 U.S. 61/086,445 EPD: N/A EPD: N/A EPD: N/A EPD: N/A EPD: N/A EPD: 08/05/2008 U.S. 61/086,445 U.S. 61/086,445 EXPRESSION AND USES THEREOF Pendir U.S. 61/106,062 U.S. 61/106,0			1		CO .
BIRC5 GENE EXPRESSION AND USES THEREOF Pendir GF-T			PA 200700751		
Red		U.S. 61/086,435			D 11
PCT/US2009/65153 U.S. 61/16,258 PCT/US2009/65153 PCT/US2009/65153 PCT/US2009/65153 PCT/US2009/65153 PCT/US2009/65153 PCT/US2009/65153 PCT/US2009/65153 U.S. 61/16,258 U.S.	00 0001	ED.9 <i>E</i> (2009	NT/A	BIRCS GENE EXPRESSION AND USES THEREOF	Pending
BPD: N/A PCT7/US2009/052878 U.S. 61/086,435 BIRC5 GENE EXPRESSION AND USES THEREOF Pendir GF-T GF-T GR/05/2008 U.S. 61/086,445 U.S. 61/086,445 U.S. 61/086,445 U.S. 61/086,445 D.S. 61/106,062 U.S. 61/106	08-091	FD:8/3/2006	IN/A		CE-TI
PCT/US2009/65153 U.S. 61/086,435 U.S. 61/086,445 U.S. 61/086,445 U.S. 61/086,445 U.S. 61/086,445 EPD: N/A PCT/US2009/052888 U.S. 61/086,445 EPD: 08/05/2008 U.S. 61/086,445 EXPRESSION AND USES THEREOF Pendir EXPRESSION AND USES THEREOF Pendir EXPRESSION AND USES THEREOF U.S. 61/106,062		EPD: N/A			GI-II
08-09PCT FD: 08/05/2009 EPD: 08/05/2008 U.S. 61/086,445 U.S. 61/086,445 Pendir EXPRESSION AND USES THEREOF P				NUCLEIC ACID COMPOUNDS FOR INHIBITING	
Se-OpPC1 Fp: 08/05/2008 CF-T			II C 61/086 /25	BIRC5 GENE EXPRESSION AND USES THEREOF	Pending
BPD: 08/05/2008 U.S. 61/086,445 V.S. 61/086,445 P.S. 61/08	08-09PCT	FD: 08/05/2009	0.3. 01/060,433		
U.S. 61/086,445 N/A NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK FAMILY GENE EXPRESSION AND USES THEREOF Pendir GF-T					GF-TI
O8-10P1 FD:8/5/2008 N/A PLK FAMILY GENE EXPRESSION AND USES THEREOF GF-T				NUCLEIC ACID COMPOUNDS FOR INTURITING	
O8-10P1		0.3. 01/060,443			Pending
Repd: N/A PCT/US2009/052888 U.S. 61/086,445 U.S. 61/086,445 Pendir GF-T Pendir GF-T Pendir GF-T Pendir GF-T U.S. 61/106,062 U.S. 61/106,	08-10P1	FD:8/5/2008	N/A		1 chang
Decompositions for inhibiting Pendir		22,0,0,1200			GF-TI
O8-10PCT FD: 08/05/2009 U.S. 61/086,445 PLK FAMILY GENE EXPRESSION AND USES THEREOF Pendir GF-T					
08-10PCT		PCT/US2009/052888			
Sept. Sept	00.4000	*** A0 10 # 10 000	U.S. 61/086,445	1	Pending
Delication	08-10PCT	FD: 08/05/2009	,	EXPRESSION AND USES THEREOF	OF TI
08-16P1		EPD: 08/05/2008			GF-11
08-16P1		111111111111111111111111111111111111111		COMPOSITIONS AND METHODS FOR	
D D D D D D D D D D					Pending
PCT/US2009/60930	08-16P1	U.S. 61/106,062	N/A	(_
08-16PCT					. D
08-16PCT		DCT/II 122000/60020		DROCESSES AND COMPOSITIONS FOR	
08-16PCT FD:10/16/2009 U.S. 61/106,062 U.S. 61/106,062 U.S. 61/167,379 GENE SILENCING THERAPEUTICS D O8-16US FD: 10/16/2009 U.S. 61/106,062 U.S. 61/106,062 U.S. 61/167,379 FP. 10/16/2008 O8-17P1 U.S. 61/116,258 N/A O8-17P1 U.S. 61/116,258 D PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pending D COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS TRIGGERED RELEASE THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS TRIGGERED RELEASE THERAPEUTICS		FC1/032009/00930			Pending
D EPD: 10/16/2008 U.S. 12/580,250 FD: 10/16/2009 EPD: 10/16/2009 EPD: 10/16/2008 U.S. 61/106,062 U.S. 61/167,379 EPD: 10/16/2008 U.S. 61/167,379 EPD: 10/16/2008 PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pending TRIGGERED RELEASE THERAPEUTICS Pending TRIGGERED RELEASE THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	08-16PCT	FD:10/16/2009		· ·	ronding
U.S. 12/580,250 08-16US FD: 10/16/2009 EPD: 10/16/2008 U.S. 61/106,062 U.S. 61/167,379 EPD: 10/16/2008 COMPOSITIONS FOR TRIGGERED RELEASE THERAPEUTICS Pendir TRIGGERED RELEASE THERAPEUTICS Pendir TRIGGERED RELEASE THERAPEUTICS D COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pendir TRIGGERED RELEASE THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS			U.S. 61/16/,3/9		D
08-16US FD: 10/16/2009 U.S. 61/106,062 U.S. 61/167,379 EPD: 10/16/2008 U.S. 61/167,379 EPD: 10/16/2008 U.S. 61/167,379 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS D PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS D COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS TRIGGERED RELEASE THERAPEUTICS					
08-16US FD: 10/16/2009 U.S. 61/160,062 U.S. 61/167,379 GENE SILENCING THERAPEUTICS D COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS PCT/US2009/65153 U.S. 61/167,379 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS		U.S. 12/580,250			- ·
D EPD: 10/16/2008 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS PCT/US2009/65153 U.S. 61/116,258 Pendin COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	00 16110	ED. 10/14/2000	U.S. 61/106,062		Pending
EPD: 10/16/2008 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pendir D PCT/US2009/65153 U.S. 61/116 258 Pendir TRIGGERED RELEASE THERAPEUTICS COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	08-1003	FD: 10/10/2009	U.S. 61/167,379	GENE SILENCING TREASFEUTICS	מ
08-17P1 U.S. 61/116,258 N/A COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS Pendin D PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS		EPD: 10/16/2008			2
08-17P1 U.S. 61/116,258 N/A D PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS					
PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS				TRIGGERED RELEASE THERAPEUTICS	Pending
PCT/US2009/65153 COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	08-17P1	U.S. 61/116,258	N/A		-
TRIGGERED RELEASE THERAPEUTICS				·	D
TRIGGERED RELEASE THERAPEUTICS		PCT/US2009/65153		COMPOSITIONS AND METHODS FOR	
			TI 0 (1/11/070		
U0-1/FC1 FD: 11/19/2009 Pendir	08-17PCT	FD: 11/19/2009	U.S. 61/116,258		Pending
EPD: 11/19/2008		EPD: 11/19/2008	,	COMPOSITIONS AND APPROPRIATE	
COMPOSITIONS AND METHODS FOR EFFICIENT DELIVERY OF GENE SIL ENCING Pandin					Pending
08-18P1 U.S. 61/141,080 N/A THERAPEUTICS Pending	08-18P1	ILS. 61/141 080	N/A		rending
00-1011 05. 01/141,000 10/A 11/ERALEOTICS	00 101 1	U.D. 02/171,000		AILEGI BOTTOS	D
		·			_

08-19P1	U.S. 61/119,624	N/A	RNA OLIGONUCLEOTIDES AND RNA COMPLEXES COMPRISING ACYLCIC NUCLEOMONOMERS	Pending CM-RC
08-19P2	U.S. 61/252,085 FD: 10/15/2009	N/A	RNA COMPLEXES COMPRISING ACYCLIC NUCLEOMONOMERS	Pending CO
08-19PCT	PCT/US2009/66610 FD: 12/3/2009 EPD 12/3/2008	U.S. 61/119,624 U.S. 61/252,085	UsiRNA COMPLEXES	Pending
09-01P1	U.S. 61/145,177 FD: 01/16/2009	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING FABP FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
09-02P1	U.S. 61/167,379 FD: 4/7/2009	N/A	COMPOSITIONS AND METHODS FOR EFFICIENT DELIVERY OF GENE SILENCING THERAPEUITCS	Pending D
09-03P1	U.S. 61/258,115	N/A	AMINO ACID-BASED NANOPARTICLE FORMULATIONS	Pending D

(certain of following may have been abandoned or transferred, or not fully prosecuted)

Client Case No.	Title	Country	App. No.	Filing Date	Pat. No
00-02US	BIMODAL EMULSIONS OF TAXANES AND BUTYRATE POLYALCOHOL ESTERS	US	09/631,246	08/02/2000	
00-03CIP	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS	US	11/537,468	09/29/2006	
00-03DIV	LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS	US	10/879,814	06/28/2004	
00-03PCT	COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM	PCT	PCT/US2007/061881	02/08/2007	
00-03PCT2	INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM	PCT	PCT/US2007/079994	09/28/2007	
00-03US	LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND PREVENTION OF BREAST CANCER	US	09/678,591	10/03/2000	6,894,026
00-06US	ADMINISTRATION OF APOMORPHINE FOR TREATING PREMATURE EJACULATION	US	09/644,406	08/23/2000	
01-01EP	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	ЕРО	02780887.2	09/22/2003	
01-01PCT	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	PCT	PCT/US2002/20171	06/24/2002	
01-01US	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	US	09/891,630	06/25/2001	
02-01AU	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Australia	2003269874	05/19/2003	
02-01 CA	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Canada	2,482,161	10/12/2004	
02-01CIP	CARBOXYLATE SALTS OF GALANTAMINE AND THEIR PHARMACEUTICAL USE	US	10/831,031	04/23/2004	
02-01CIP2	COMPOSITIONS AND METHODS USING ACETYLCHOLINESTERASE (ACE) INHIBITORS TO TREAT CENTRAL NERVOUS SYSTEM (CNS) DISORDERS IN MAMMALS	US	11/112,950	04/22/2005	
02-01CIP-CA	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	Canada	2,564,353	10/10/2006	
02-01CIP-EP	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	EPO	05758604.2	11/14/2006	

ACKNOWLEDGEMENT OF GRANTOR INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE

	GALANTAMINE SALTS, METHOD OF			10/20/2006	· · · · · · · · · · · · · · · · · · ·
02-01CIP-JP	PRODUCING IT AND NASAL	Japan	2007-509671	10/20/2000	
02 01011 -31	COMPOSITION THEREOF	Jupan	2007. 303071		
	GALANTAMINE SALTS, METHOD OF		+	10/23/2006	·-
02-01CIP-MX	PRODUCING IT AND NASAL	Mexico	PA/a/2006/012269	10/23/2000	
02-01CH -WA	COMPOSITION THEREOF	MICAICO	1 AJ aJ 2000/012209		
	GALANTAMINE SALTS, METHOD OF			04/22/2005	
02 01 CID DOT	PRODUCING IT AND NASAL	PCT	DCT//102005/012776	04/22/2003	
02-01CIP-PCT	·	PC1	PCT/US2005/013776		
	COMPOSITION THEREOF			11/05/0004	
00 01ED	ADMINISTRATION OF	EDO	02751771 0	11/05/2004	
02-01EP	ACETYLCHOLINESTERASE INHIBITORS	EPO	03751761.2		
	TO THE CEREBRAL SPINAL FLUID			004164005	
	ADMINISTRATION OF		0.51.000.00	03/16/2005	
02-01HK	ACETYLCHOLINESTERASE INHIBITORS	Hong Kong	05102306.0		
	TO THE CEREBRAL SPINAL FLUID		·		
	ADMINISTRATION OF			08/25/2004	
02-01IL	ACETYLCHOLINESTERASE INHIBITORS	Israel	163731		
	TO THE CEREBRAL SPINAL FLUID				
	ADMINISTRATION OF			11/05/2004	
02-01 IN	ACETYLCHOLINESTERASE INHIBITORS	India	1664/KOLNP/2004		
	TO THE CEREBRAL SPINAL FLUID				
	ADMINISTRATION OF	•		11/22/2004	
02-01JP	ACETYLCHOLINESTERASE INHIBITORS	Japan	2004-517563		
	TO THE CEREBRAL SPINAL FLUID	,	· ·		
	ADMINISTRATION OF			05/19/2003	535192
02-01NZ	ACETYLCHOLINESTERASE INHIBITORS	New Zealand	535192		
	TO THE CEREBRAL SPINAL FLUID				
00.0171	CSF ADMINISTRATION OF ACE	***	(0/000 100	05/21/2002	
02-01 P1	INHIBITORS	US	60/382,122		
	ADMINISTRATION OF			05/19/2003	
02-01PCT	ACETYLCHOLINESTERASE INHIBITORS	PCT	PCT/US03/15653		
	TO THE CEREBRAL SPINAL FLUID				
	ADMINISTRATION OF			05/15/2003	
02-01US	ACETYLCHOLINESTERASE INHIBITORS	US	10/439,108	00/13/2003	
02 0100	TO THE CEREBRAL SPINAL FLUID	05	10, 155,100		
	ADMINISTRATION OF			09/15/2004	2004/742
02-01 ZA	ACETYLCHOLINESTERASE INHIBITORS	South Africa	2004/7420	03/13/2001	0
OZ OIZX	TO THE CEREBRAL SPINAL FLUID	Bouin mineu	2004,7420		"
	COMPOSITIONS AND METHODS FOR			11/30/2004	··
02-02AU	ENHANCED MUCOSAL DELIVERY OF	Australia	2003267965	11/50/2004	
02-02AU	INTERFERON BETA	Australia	2003207903		
	COMPOSITIONS AND METHODS FOR			06/18/2003	
00.0004	ENHANCED MUCOSAL DELIVERY OF	Camada	2 496 521	00/18/2003	
02-02CA		Canada	2,486,531		
	INTERFERON BETA			10/10/0007	
00 000037	COMPOSITIONS AND METHODS FOR	***	11/050 505	12/10/2007	
02-02CON	ENHANCED MUCOSAL DELIVERY OF	US	11/953,685		
	INTERFERON BETA	.=.		01/0//2027	
	COMPOSITIONS AND METHODS FOR	-	00-1001-	01/24/2005	
02-02EP	ENHANCED MUCOSAL DELIVERY OF	EPO	03748913.5		
	INTERFERON BETA				
	COMPOSITIONS AND METHODS FOR			11/11/2004	
02-02IL	ENHANCED MUCOSAL DELIVERY OF	Israel	165172		
	INTERFERON BETA		1		

	COMPOSITIONS AND METHODS FOR			12/02/2004	536939
02-02NZ	ENHANCED MUCOSAL DELIVERY OF	New Zealand	536939	12/02/2004	330939
02-02112	INTERFERON BETA	New Zealand	330939		
	COMPOSITIONS AND METHODS FOR			06/28/2002	
02-02P1	ENHANCED MUCOSAL DELIVERY OF	US	60/393,066	00/20/2002	1
02-02F1	INTERFERON BETA (IFN-BETA)		00/393,000		
	COMPOSITIONS AND METHODS FOR			06/18/2003	
02-02PCT	ENHANCED MUCOSAL DELIVERY OF	PCT	DCT/I ICO2/10261	00/18/2003	
02-02PC1	INTERFERON BETA	PCI	PCT/US03/19261		
	COMPOSITIONS AND METHODS FOR			06/16/2002	
00.00110		TTC	10//60 450	06/16/2003	
02-02US	ENHANCED MUCOSAL DELIVERY OF	US	10/462,452		
	INTERFERON BETA			11/20/2004	2004/065
00 00774	COMPOSITIONS AND METHODS FOR	G1 A.C.	0004/0650	11/29/2004	2004/965
02-02ZA	ENHANCED MUCOSAL DELIVERY OF	South Africa	2004/9652		2
	INTERFERON BETA			06/04/0000	
	COMPOSITIONS AND METHODS FOR	*		06/24/2003	
	MODULATING PHYSIOLOGY OF			•	
02-03AU	EPITHELIAL JUNCTIONAL ADHESION	Australia	2003279750		1
	MOLECULES FOR ENHANCED		2003277730		1
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			06/24/2003	
	MODULATING PHYSIOLOGY OF				
02-03CA	EPITHELIAL JUNCTIONAL ADHESION	Canada	2,487,712		
02-03CA	MOLECULES FOR ENHANCED	Cunada	2,107,712		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			01/24/2005	
	MODULATING PHYSIOLOGY OF				
02-03EP	EPITHELIAL JUNCTIONAL ADHESION	EPO	03742185.6	1	
02 0522	MOLECULES FOR ENHANCED	23.0	057 12105.0		
	MUCOSAL DELIVERY OF THERAPEUTIC				
,	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			11/29/2004	
	MODULATING PHYSIOLOGY OF				
02-03IL	EPITHELIAL JUNCTIONAL ADHESION	Israel	165441		
02 03IE	MOLECULES FOR ENHANCED	151401			
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			12/17/2004	ľ
02-03IN	MODULATING PHYSIOLOGY OF				1
	EPITHELIAL JUNCTIONAL ADHESION	India	1951/KOLNP/2004		
	MOLECULES FOR ENHANCED	noiu	1931/1602/172001		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			12/28/2004	
	MODULATING PHYSIOLOGY OF				
02-03JP	EPITHELIAL JUNCTIONAL ADHESION	Japan	2004-517800		
02-03JF	MOLECULES FOR ENHANCED	Japan	2007-317000		
_	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS		1	1	

	COMPOSITIONS AND METHODS FOR		<u> </u>	06/24/2003	
	MODULATING PHYSIOLOGY OF			00/24/2003	
	EPITHELIAL JUNCTIONAL ADHESION				
02-03NZ	MOLECULES FOR ENHANCED	New Zealand	537569		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS	,			
	COMPOSITIONS AND METHODS FOR			06/28/2002	-
	MODULATING PHYSIOLOGY OF				
	EPITHELIAL JUNCTIONAL ADHESION	***	(0.100.0.7.10		
02-03P1	MOLECULES FOR ENHANCED	US	60/392,512		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			06/24/2003	
	MODULATING PHYSIOLOGY OF				-
02-03PCT	EPITHELIAL JUNCTIONAL ADHESION	PCT	PCT/US03/19994		
02-031 C1	MOLECULES FOR ENHANCED	101	101/0303/17/74		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS	······			
	COMPOSITIONS AND METHODS FOR			06/24/2003	
	MODULATING PHYSIOLOGY OF				
02-03US	EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED	US	10/601,953		
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR	· · · · · · · · · · · · · · · · · · ·		12/21/2004	2004/102
	MODULATING PHYSIOLOGY OF	÷		12/21/2001	87
	EPITHELIAL JUNCTIONAL ADHESION	~			"
02-03ZA	MOLECULES FOR ENHANCED	South Africa	2004/10287		
•	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			06/11/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2	United Arab			
02-04AE	RECEPTOR-BINDING PEPTIDES AND	Emirates	320/2005		
	METHODS FOR TREATING AND	Emmano			
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR				
00.04434	ENHANCED MUCOSAL DELIVERY OF Y2	A:-			
02-04AM	RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND	Armenia			
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			12/17/2003	-
	ENHANCED MUCOSAL DELIVERY OF Y2			12/1//2003	
02-04AU	RECEPTOR-BINDING PEPTIDES AND	Australia	2003299722		
02-04AU	METHODS FOR TREATING AND	1 Iusu unu	2003277722		
	PREVENTING OBESITY	•			
02-04A Z	COMPOSITIONS AND METHODS FOR			<u> </u>	
	ENHANCED MUCOSAL DELIVERY OF Y2				
	RECEPTOR-BINDING PEPTIDES AND	Azerbaijan			
	METHODS FOR TREATING AND	Ţ			
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/09/2005	1
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04BB	RECEPTOR-BINDING PEPTIDES AND	Barbados	2001/1146		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				

	COMPOSITIONS AND METRIODS FOR			06/16/2005	
	COMPOSITIONS AND METHODS FOR			06/16/2005	
7771000	ENHANCED MUCOSAL DELIVERY OF Y2		0016605.6		
02-04BR	RECEPTOR-BINDING PEPTIDES AND	Brazil	0316685-6		
1	METHODS FOR TREATING AND			ļ	
	PREVENTING OBESITY				,
	COMPOSITIONS AND METHODS FOR				ļ
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04BY	RECEPTOR-BINDING PEPTIDES AND	Belarus			
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/16/2005	
02-04BZ	ENHANCED MUCOSAL DELIVERY OF Y2				
	RECEPTOR-BINDING PEPTIDES AND	Belize	BZ388.05]	
02 0 132	METHODS FOR TREATING AND	Donie	22500.05		
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			12/17/2003	
	ENHANCED MUCOSAL DELIVERY OF Y2			12/1//2005	
02-04CA	·	Camada	2.510.100	·	
02-04CA	RECEPTOR-BINDING PEPTIDES AND	Canada	2,510,199		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY			10/00/0000	7 105 501
	COMPOSITIONS AND METHODS FOR			12/23/2003	7,186,691
	ENHANCED MUCOSAL DELIVERY OF Y2		10717.000		
02-04CIP	RECEPTOR-BINDING PEPTIDES AND	US	10/745,069		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			02/17/2004	7,229,966
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04CIP3	RECEPTOR-BINDING PEPTIDES AND	US	10/780,325		
	METHODS FOR TREATING AND		· ·		
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			08/09/2006	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04CIP3-CA	RECEPTOR-BINDING PEPTIDES AND	Canada	2,555,826		
	METHODS FOR TREATING AND		, ,		
,	PREVENTING OBESITY				.
	COMPOSITIONS AND METHODS FOR			07/20/2006	
	ENHANCED MUCOSAL DELIVERY OF Y2			0772072000	
02-04CIP3-EP	RECEPTOR-BINDING PEPTIDES AND	EPO	05723353.8		
02-04CH 5-LI	METHODS FOR TREATING AND	LIO	03723333.6		
	PREVENTING OBESITY		·		
	COMPOSITIONS AND METHODS FOR				
	ENHANCED MUCOSAL DELIVERY OF Y2				
02.040102.117		TT T/			
02-04CIP3-HK	RECEPTOR-BINDING PEPTIDES AND	Hong Kong			
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
02-04CIP3-JP	COMPOSITIONS AND METHODS FOR			08/15/2006	
	ENHANCED MUCOSAL DELIVERY OF Y2				
	RECEPTOR-BINDING PEPTIDES AND	Japan	2006-553374		
	METHODS FOR TREATING AND	•			
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			08/16/2006	
	ENHANCED MUCOSAL DELIVERY OF Y2				
	RECEPTOR-BINDING PEPTIDES AND	Mexico	PA/a/2006/009331		
02-04CIP3-MX	RECEPTOR-BUILDING PEPTIDES AND	MICVICO	1 17401700000000000000000000000000000000	l .	
02-04CIP3-MX	METHODS FOR TREATING AND	IVICAICO	1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		

	COMPOSITIONS AND METHODS FOR			02/17/2005	
02-04CIP3- PCT	ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND	PCT	PCT/US2005/005339	02/17/2003	
02-04CIP4	PREVENTING OBESITY COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/869,649	06/16/2004	7,186,692
02-04CN	COMPOSITIONS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR- BINDING PEPTIDES AND USES FOR TREATING OBESITY	China	200380106468.9	06/17/2005	
02-04CO	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Colombia	05-058.645	06/16/2005	
02-04CON2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	us	10/768,288	01/30/2004	7,157,426
02-04CON2- DIV	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE	US	11/467,509	08/25/2006	
02-04CON2- DIV2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE	US		e e e e e e e e e e e e e e e e e e e	
02-04CR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Costa Rica	6789	06/17/2005	
02-04DIV1	COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY	US	11/561,331	11/17/2006	
02-04DIV3	METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR- BINDING PEPTIDES FOR TREATING AND PREVENTING OBESITY	US	11/563,587	11/27/2006	
02-04DIV4	COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES	US	11/561,825	11/20/2006	
02-04DIV5	A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR- BINDING PEPTIDES	US	11/562,913	11/22/2006	
02-04D Z	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Algeria	050217	06/20/2005	050217

	COMPOSITIONS AND METHODS FOR			07/18/2005	008829
	ENHANCED MUCOSAL DELIVERY OF Y2			07/16/2003	000029
02-04EA	RECEPTOR-BINDING PEPTIDES AND	EAPO	200501007		
02-04EA	METHODS FOR TREATING AND	LAFO	200301007		
	1	•			1
	PREVENTING OBESITY			06/17/2005	
	COMPOSITIONS AND METHODS FOR			06/17/2005	
00.0476	ENHANCED MUCOSAL DELIVERY OF Y2	273	05 5000		1
02-04EC	RECEPTOR-BINDING PEPTIDES AND	Ecuador	05-5839		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY			·	
	COMPOSITIONS AND METHODS FOR			06/16/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2	_			
02-04EG	RECEPTOR-BINDING PEPTIDES AND	Egypt	2005/06/306		į
	METHODS FOR TREATING AND				
	PREVENTING OBESITY	·			
	COMPOSITIONS AND METHODS FOR			12/17/2003	İ
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04EP	RECEPTOR-BINDING PEPTIDES AND	EPO	03800002.2		
	METHODS FOR TREATING AND				ŀ
	PREVENTING OBESITY				·
	COMPOSITIONS AND METHODS FOR			06/15/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04GE	RECEPTOR-BINDING PEPTIDES AND	Georgia	8901/01/-05		
	METHODS FOR TREATING AND	J			ļ
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			02/27/2006	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04HK	RECEPTOR-BINDING PEPTIDES AND	Hong Kong	06102556.6		
02 0 11111	METHODS FOR TREATING AND	**************************************	001020000		
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/17/2005	W-
	ENHANCED MUCOSAL DELIVERY OF Y2		÷	00/1//2005	0020050
02-04ID	RECEPTOR-BINDING PEPTIDES AND	Indonesia	W-00200501620		1620
02-0-115	METHODS FOR TREATING AND	Indonesia	W-00200501020		1020
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			03/03/2008	-
	ENHANCED MUCOSAL DELIVERY OF Y2			03/03/2008	
02-04ID-DIV	RECEPTOR-BINDING PEPTIDES AND	Indonesia	W-00200800724		
02-041D-D1V	METHODS FOR TREATING AND	ilidollesia	W-00200800724		
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR		-	06/09/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2			00/09/2003	
00.0477		T1	160100		
02-04 IL	RECEPTOR-BINDING PEPTIDES AND	Israel	169108		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY			10-11-51-5-5	
	COMPOSITIONS AND METHODS FOR			07/15/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2	_			
02-04 IN	RECEPTOR-BINDING PEPTIDES AND	India	1373/KOLNP/2005		·
•	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
· 	COMPOSITIONS AND METHODS FOR			06/17/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04JP	RECEPTOR-BINDING PEPTIDES AND	Japan	2005-502646		1
	METHODS FOR TREATING AND	-			
	PREVENTING OBESITY		i	1	

	COMPOSITIONS AND METHODS FOR	[···			
	ENHANCED MUCOSAL DELIVERY OF Y2				•
02-04KG	RECEPTOR-BINDING PEPTIDES AND	V.m. Damuklia			
02-04 K G		Kyrgyz Republic			
	METHODS FOR TREATING AND		•		
	PREVENTING OBESITY			05/00/005	
•	COMPOSITIONS AND METHODS FOR		•	05/30/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2	Republic of			
02-04KR	RECEPTOR-BINDING PEPTIDES AND	Korea	10-2005-7009727		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR				
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04KZ	RECEPTOR-BINDING PEPTIDES AND	Kazakhstan			
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/15/2005	28337
	ENHANCED MUCOSAL DELIVERY OF Y2	,			
02-04MA	RECEPTOR-BINDING PEPTIDES AND	Morocco	28337/2005		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY			· ·	
	COMPOSITIONS AND METHODS FOR				
	ENHANCED MUCOSAL DELIVERY OF Y2	D 11: 6			ĺ
02-04 M D	RECEPTOR-BINDING PEPTIDES AND	Republic of			
	METHODS FOR TREATING AND	Moldova			
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/08/2005	2654
	ENHANCED MUCOSAL DELIVERY OF Y2			55/55/2555	200 .
02-04MN	RECEPTOR-BINDING PEPTIDES AND	Mongolia	3587		
02 0 11/21 (METHODS FOR TREATING AND	2,20,180,18	2507		
	PREVENTING OBESITY		•	İ	
	COMPOSITIONS AND METHODS FOR	:	*	06/17/2005	-
	ENHANCED MUCOSAL DELIVERY OF		•	00/1//2005	
02-04MX	PEPTIDE YY AND METHODS FOR	Mexico	PA/a/2005/006572		
	TREATING AND PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/16/2005	
•	ENHANCED MUCOSAL DELIVERY OF			00/10/2003	
02-04NI	PEPTIDE YY AND METHODS FOR	Nicaragua	2005-0108		
	TREATING AND PREVENTING OBESITY	.	4		
	COMPOSITIONS AND METHODS FOR			07/14/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2			07/14/2003	,
00.04NO		Name	2005 2420		
02-04NO	RECEPTOR-BINDING PEPTIDES AND	Norway	2005 3430		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY			10/15/0000	
	COMPOSITIONS AND METHODS FOR			12/17/2003	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04NZ	RECEPTOR-BINDING PEPTIDES AND	New Zealand	540317		
•	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/15/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04OM	RECEPTOR-BINDING PEPTIDES AND	Oman	PCT 56/2005		\
	METHODS FOR TREATING AND		•		1.
	PREVENTING OBESITY				1

PATENT

REEL: 023973 FRAME: 0323

	COMPOSITIONS AND METHODS FOR			10/17/0000	Т
	COMPOSITIONS AND METHODS FOR			12/17/2003	
00.047007	ENHANCED MUCOSAL DELIVERY OF Y2	D.CIT	200000000000000000000000000000000000000		
02-04PCT	RECEPTOR-BINDING PEPTIDES AND	PCT	PCT/US03/40538		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY	· · · · · · · · · · · · · · · · · · ·			
	COMPOSITIONS AND METHODS FOR		,	06/17/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2				1
02-04PH	RECEPTOR-BINDING PEPTIDES AND	Philippines	1-2005-501170		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			_	
	ENHANCED MUCOSAL DELIVERY OF Y2	Russian			
02-04RU	RECEPTOR-BINDING PEPTIDES AND			Ì	
	METHODS FOR TREATING AND	Federation			
	PREVENTING OBESITY				
<u> </u>	COMPOSITIONS AND METHODS FOR			05/13/2005	112496
	ENHANCED MUCOSAL DELIVERY OF Y2				
02-04SG	RECEPTOR-BINDING PEPTIDES AND	Singapore	200503079-6		
02 0150	METHODS FOR TREATING AND	Singapore	2002050770		'
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/04/2007	
	ENHANCED MUCOSAL DELIVERY OF Y2			00/04/2007	
02-04SG2	RECEPTOR-BINDING PEPTIDES AND	Singapore	200703952-2		
02-04302	METHODS FOR TREATING AND	Singapore	200703932-2		
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			-	
	ENHANCED MUCOSAL DELIVERY OF Y2				
00.0455	1	TD - 111-1-4			
02-04TJ	RECEPTOR-BINDING PEPTIDES AND	Tajikistan			
	METHODS FOR TREATING AND		•	}	ł
	PREVENTING OBESITY				-
	COMPOSITIONS AND METHODS FOR		•		}
00.04777.4	ENHANCED MUCOSAL DELIVERY OF Y2	m 1			
02-04TM	RECEPTOR-BINDING PEPTIDES AND	Turkmenistan			
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			06/17/2005	SN05 162
	ENHANCED MUCOSAL DELIVERY OF Y2				•
02-04TN	RECEPTOR-BINDING PEPTIDES AND	Tunisia	05162		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
•	COMPOSITIONS AND METHODS FOR			08/11/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2	Trinidad and			
02-04TT	RECEPTOR-BINDING PEPTIDES AND	Tobago	TT/A/2005/00106		
	METHODS FOR TREATING AND	Tobago			
	PREVENTING OBESITY		L		
	COMPOSITIONS AND METHODS FOR			07/18/2005	
	ENHANCED MUCOSAL DELIVERY OF Y2			•	
02-04UA	RECEPTOR-BINDING PEPTIDES AND	Ukraine	200507097		
	METHODS FOR TREATING AND			1	
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			12/17/2002	7,166,575
	ENHANCED MUCOSAL DELIVERY OF			12,1,,2002	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
02-04US	PEPTIDE YY AND METHODS FOR	US	10/322,266		
	TREATING AND PREVENTING OBESITY				
	TALATHO AND FACTORING OBESITE		1		

	COMPOSITON FOR ENHANCED			07/11/2005	<u> </u>
02-04VN	MUCOSAL DELIVERY OF Y2 RECEPTOR- BINDING PEPTIDES AND USE OF THESE PEPTIDES IN MANUFACTURING MEDICAMENT FOR TREATMENT AND PREVE	Viet Nam	1-2005-00953	07/11/2003	
02-04Z A	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	South Africa	2005/04875	06/14/2005	2005/048 75
03-01P1	METHOD AND COMPOSITIONS TO TREAT MALE INFERTILITY	US	60/444,032	01/31/2003	
03-01PCT	METHOD AND COMPOSITIONS FOR TREATING MALE INFERTILITY	PCT	PCT/US04/02400	01/27/2004	
03-05P1	INTRANASAL ADMINISTRATION OF TRIPTANS	US	60/464,671	04/22/2003	
03-05PCT	INTRANASAL ADMINISTRATION OF TRIPTANS	PCT	PCT/US2004/011445	04/14/2004	
03-05US	INTRANASAL ADMINISTRATION OF TRIPTANS	US	10/824,452	04/14/2004	
03-06P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	US	60/469,079	05/08/2003	
03-06PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	PCT	PCT/US2004/014261	05/07/2004	
03-06US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	US	10/840,536	05/06/2004	
03-07CA	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	Canada	2,523,870	10/27/2005	
03-07CN	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	China	200480018784.5	12/30/2006	
03-07EP	METHOD FOR DIAGNOSING AND TREATING CANCER	EPO	04751031.8	04/30/2004	
03-07JP	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	Japan	2006-514176	10/28/2005	
03-07MX	METHOD FOR DIAGNOSING AND TREATING CANCER	Mexico	PA/a/2005/011644	10/28/2005	
03-07NO	METHOD FOR DIAGNOSING AND TREATING CANCER	Norway	2005 5449	11/17/2005	
03-07P1	METHOD FOR DIAGNOSING AND TREATING CANCER	US	60/466,905	04/30/2003	
03-07PCT	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	PCT	PCT/US2004/013436	04/30/2004	
03-07US	METHOD FOR DIAGNOSING AND TREATING CANCER	US	10/836,421	04/30/2004	
03-08CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Canada	2,528,465	12/06/2005	
03-08EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	EPO	04754279.0	01/05/2006	

03-08JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Japan	2006-533559	12/08/2005
03-08MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Mexico	PA/a/2005/013340	12/08/2005
03-08P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	US	60/477,403	06/09/2003
03-08PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	PCT	PCT/US04/17632	06/01/2004
03-08US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	US	10/862,141	06/01/2004
03-09AR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Argentina	• P04 01 02789	08/05/2004
03-09CL	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Chile	2023-2004	08/05/2004
03-09EG	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Egypt		
03-09MY	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Malaysia	PI 20043210	08/06/2004
03-09P1	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/493,226	08/07/2003
03-09P2	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/501,170	09/08/2003
03-09 P 3	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/510,785	10/10/2003
03-09P4	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/517,290	11/04/2003
03-09P5	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/518,812	11/10/2003
03-09PE	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Peru	754-2004	08/05/2004

			· · · · · · · · · · · · · · · · · · ·	1	
	COMPOSITIONS AND METHODS FOR			08/04/2004	
	ENHANCED MUCOSAL DELIVERY OF Y2				
03-09SA	RECEPTOR-BINDING PEPTIDES AND	Saudi Arabia	04250240		
•	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	COMPOSITIONS AND METHODS FOR			08/06/2004	
	ENHANCED MUCOSAL DELIVERY OF Y2				
03-09TW	RECEPTOR-BINDING PEPTIDES AND	Taiwan	93123699		
	METHODS FOR TREATING AND				
	PREVENTING OBESITY				
	PROTEIN-FREE FORMULATION OF			08/06/2004	
03-09VE	PEPTIDE YY SUITABLE FOR	Venezuela	2004-01280	00/00/2001	
05 05 12	INTRANASAL ADMINISTRATION	, , , , , , , , , , , , , , , , , , , ,			
	METHOD FOR TREATING PARKINSON'S			10/24/2003	
03-11P1	DISEASE USING APOMORPHINE AND	US	60/514,382	10/24/2003	
03-1111	APOMORPHINE PRODRUGS	03	00/514,582		
	TREATMENT OF PARKINSON'S DISEASE			10/21/2004	
				10/21/2004	
03-11PCT	USING APOMORPHINE IN COMBINATION WITH AN	PCT	PCT/US2004/034929		
	APOMORPHINE PRODRUG			10/10/0004	
00 11770	METHOD FOR TREATING PARKINSON'S	***	10/064 007	10/12/2004	
03-11US	DISEASE USING APOMORPHINE AND	US	10/964,327		
	APOMORPHINE PRODRUGS				
03-12CON	PHAGE DISPLAYED TRP CAGE LIGANDS	US	11/955,207	12/12/2007	
03-12P1	PHAGE DISPLAYED TRP CAGE LIGANDS	US	60/515,533	10/29/2003	
03-12US	PHAGE DISPLAYED TRP CAGE LIGANDS	US	10/976,942	10/29/2004	7,329,725
	METHODS OF COMPARING Y2 RECEPTOR			02/09/2004	
04-01P1	BINDING COMPOUND FORMULATIONS	US	60/543,111		
04-0111	BY BIOEQUIVILENCE METHODS USING	US			
	EXTRACTED HUMAN PLASMA				
04.01007	METHODS FOR DETERMINING THE	PCT	DCT/IIIO5/04160	02/09/2005	
04-01PCT	AMOUNT OF PEPTIDE YY IN BLOOD	PCI	PCT/US05/04168		
04.01110	METHODS FOR DETERMINING THE	770	11/05/10/5	02/09/2005	
04-01US	AMOUNT OF PEPTIDE YY IN BLOOD	US	11/054,245		
	COMPOSITIONS AND METHODS FOR			12/08/2006	
04- 04AU	ENHANCED MUCOSAL DELIVERY OF	Australia 2005247369			
	PARATHYROID HORMONE				
	COMPOSITIONS AND METHODS FOR			11/09/2006	<u> </u>
04-04CA	ENHANCED MUCOSAL DELIVERY OF	Canada	2,567,056	1170372000	·
	PARATHYROID HORMONE	Canada	2,507,050	-	
	GRAS COMPOSITION FOR INTRANASAL			10/06/2005	
04-04CIP	DELIVERY OF PARATHYROID	US	11/246,450	10/00/2005	
04-04011	HORMONE	OS	11/240,430		
	METHOD OF TREATING OSTEOPOROSIS			10/06/2005	
04.04/7777		TTG	11/046 406	10/00/2003	
04-04CIP2	USING INTRANASAL PARATHYROID	US	11/246,406		
04.045770	HORMONE	TTO	11/045.554	00/00/000	
04-04CIP3	STABILIZED TERIPARATIDE SOLUTION	US	11/347,554	02/03/2006	
04-04CIP4	METHOD OF DELIVERING PARATHYROID	US	11/347,551	02/03/2006	
	HORMONE TO A HUMAN	- -			
04-04CIP5	STABLE PHARMACEUTICAL DOSAGE	US	11/390,940	03/27/2006	1
- OF OTOLI J	FORMS OF TERIPARATIDE		111070,710		
04_04CTP_ATT	PTH FORMULATIONS AND METHODS OF	Australia	2006299887	04/01/2008	
04-04CIP-AU	USE	Ausualia	2000233007		
01-04CH -110					
04-04CIP-CA	PTH FORMULATIONS AND METHODS OF	Canada		04/07/2008	

04-04CIP-CN	PTH FORMULATIONS AND METHODS OF USE	China		06/05/2008
04-04CIP-EP	PTH FORMULATIONS AND METHODS OF USE	EPO	06749687.7	03/28/2008
04-04CIP-IL	PTH FORMULATIONS AND METHODS OF USE	Israel	190583	04/02/2008
04-04CIP-IN	PTH FORMULATIONS AND METHODS OF USE	India	2807/DELNP/2008	04/03/2008
04-04CIP-JP	PTH FORMULATIONS AND METHODS OF USE	Japan		04/01/2008
04-04CIP-KR	PTH FORMULATIONS AND METHODS OF USE	Republic of Korea	10-2008-7010885	05/06/2008
04-04CIP-MX	PTH FORMULATIONS AND METHODS OF USE	Mexico	MX/a/2008/004575	04/04/2008
04-04CIP-NZ	PTH FORMULATIONS AND METHODS OF USE	New Zealand	567871	05/02/2008
04-04CIP-PCT	PTH FORMULATIONS AND METHODS OF USE	PCT	PCT/US2006/013377	04/10/2006
04-04CIP-SG	PTH FORMULATIONS AND METHODS OF USE	Singapore	200802536-3	04/01/2008
04-04CIP-ZA	PTH FORMULATIONS AND METHODS OF USE	South Africa	2008/03974	05/05/2008
04-04CN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	China	20050023137.8	01/09/2007
04-04CON	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/744,745	05/04/2007
04-04DIV1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,055	10/17/2006
04-04DIV2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,061	10/17/2006
04-04DIV3	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,051	10/17/2006
04-04EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	EPO	05780065.8	12/08/2006
04-04IN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	India	6774/DELNP/2006	11/10/2006
04-04JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Japan	2007-513324	11/08/2006
04-04MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Mexico	PA/a/2006/012980	11/09/2006
04-04NO	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Norway	2006/5673	12/08/2006
04-04NZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	New Zealand	551875	12/07/2006

04-04P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF	US	60/570,113	05/10/2004	
04-04PCT	PARATHYROID HORMONE COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	PCT	PCT/US2005/016530	05/10/2005	
04-04PCT3	PTH FORMULATIONS AND METHODS OF USE	PCT	PCT/2006/38735	10/03/2006	
04-04RU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Russian Federation	2006143544/20	12/11/2006	12/11/20 6
04-04US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/126,996	05/10/2005	7,244,70
04-08AU	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Australia	2005251786	12/29/2006	
04-08CA	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Canada	2,569,137	11/29/2006	
04-08CN	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	China	200580024025.4	01/16/2007	
04-08EP	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	EPO	05757909.6	01/03/2007	
04-08IN	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	India	7041/DELNP/2006	11/23/2006	
04-08ЈР	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Japan	2007-515683	12/05/2006	
04-08KR	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Republic of Korea	10-2007-7000318	01/05/2007	
04-08MX	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Mexico	PA/a/2006/014215	12/06/2006	
04-08NO	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Norway	20070072	01/04/2007	
04-08NZ	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	New Zealand	552346	01/03/2007	

	INTRANASAL FORMULATIONS OF			06/07/2004	
04-08P1	INTERFERON BETA FREE OF	US	60/577,695		
04-06F1	STABILIZERS THAT ARE PROTEINS OR	US	00/3//693		
,	POLYPEPTIDES			.	
	INTRANASAL FORMULATIONS OF			06/07/2005	
0.4.00000000	INTERFERON BETA FREE OF	200	22222222222222		
04-08PCT	STABILIZERS THAT ARE PROTEINS OR	PCT	PCT/US2005/019908		
	POLYPEPTIDES				
	INTRANASAL FORMULATIONS OF			12/05/2006	<u> </u>
	INTERFERON BETA FREE OF			12/03/2000	
04-08US	STABILIZERS THAT ARE PROTEINS OR	US	11/570,068	· ·	
	POLYPEPTIDES				
	PEPTIDE YY FORMULATIONS HAVING			06/16/2004	
04-09P1	1	US	60/580,329	00/10/2004	
	INCREASED STABILITY			06466000	
	PEPTIDE YY FORMULATIONS HAVING			06/16/2005	
04-09PCT	INCREASED STABILITY AND	PCT	PCT/US2005/021377		
	RESISTANCE TO MICROBIAL AGENTS				
	PEPTIDE YY FORMULATIONS HAVING			12/07/2006	
04-09US	INCREASED STABILITY AND	US	11/570,223		
	RESISTANCE TO MICROBIAL AGENTS		·		
	PEPTIDE YY FORMULATIONS HAVING			06/16/2004	
04-10P1	INCREASED RESISTANCE TO	US	60/580,310		
	MICROBIAL AGENTS				
	PERMEABILIZING PEPTIDES FOR			07/07/2004	
	MODULATING PHYSIOLOGY OF				
	EPITHELIAL JUNCTIONAL ADHESION				
04-12P1	MOLECULES FOR ENHANCED	US	60/586,288	-	
	MUCOSAL DELIVERY OF THERAPEUTIC				
	COMPOUNDS				
	COMPOSITIONS AND METHODS FOR			08/13/2004	
	INTRANASAL ADMINISTRATION OF			00/13/2004	
04-13P1	INACTIVE ANALOGS OF PTH OR	US	60/601 215	4	
U4-13F1	1	US	60/601,215		
	INACTIVATED PREPARATIONS OF PTH				
·	OR PTH ANALOGS			00450005	
	COMPOSITIONS AND METHODS FOR			08/15/2005	
	INTRANASAL ADMINISTRATION OF				
04-13 US	INACTIVE ANALOGS OF PTH OR	US	11/205,255		
	INACTIVATED PREPARATIONS OF PTH			1 .	
	OR PTH ANALOGS	·			
	PERMEABILIZING PEPTIDES FOR			09/21/2004	
04-15P1	ENHANCED MUCOSAL DELIVERY OF	US	60/612,121		
	THERAPEUTIC COMPOUNDS				
	PERMEABILIZING PEPTIDES FOR	· · · · · · · · · · · · · · · · · · ·		04/01/2005	
	ENHANCED MUCOSAL DELIVERY OF				
04-15P2	MACROMOLECULAR AND SMALL	US	60/667,835		
	MOLECULE THERAPEUTIC	77			
	COMPOUNDS				
	CYCLIC PERMEABILIZING PEPTIDE FOR			09/21/2004	
04-16P1	ENHANCED MUCOSAL DELIVERY OF	US	60/612,285	03/21/2004	
04-10F1	I	US	00/012,283	. 1	
	THERAPEUTIC COMPOUNDS			04/01/0007	
04.1672	PERMEABILIZING PEPTIDES FOR	***	(0.457-07-1	04/01/2005	
04-16P2	ENHANCED MUCOSAL DELIVERY OF	US	60/667,871		
	THERAPEUTIC COMPOUNDS				
04-21P1	INTRANASAL ADMINISTRATION OF	US	60/630,786	11/23/2004	
O 1 2 1 1 1	EXENDIN PEPTIDES		1 00,020,700	1	

04-21US	INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDES	US	11/267,845	11/04/2005
04-22P1	INTRANASAL ADMINISTRATION OF NATRIURETIC AND VASODILATOR PEPTIDES	US	60/637,961	12/21/2004
05-02AU	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Australia	2006257792	12/06/2007
05-02CA	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Canada	2,611,836	12/11/2007
05-02EP	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Europe	06773192.7	01/11/2008
05-02IN	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	India	186/DELNP/2008	01/07/2008
05-02MX	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Mexico	MX/a/2007/015819	12/13/2007
05-02NZ	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	New Zealand	564131	11/30/2007
05-02P1	TRANSMUCOSAL DELIVERY OF MOLECULES CONJUGATED WITH WATER-SOLUBLE POLYMERS IN THE PRESENCE OF PERMEATION ENHANCERS	US	60/689,869	06/13/2005
05-02PCT	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	PCT	PCT/2006/023220	06/13/2006
05-02SG	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Singapore	200718025-0	11/23/2007
05-02US	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	US	11/917,340	12/12/2007
05-03P1	COMPOUNDS MODIFIED WITH LOW MOLECULAR-WEIGHT POLY (ETHYLENE GLYCOL) AND USES THEREOF	US	60/690,842	06/14/2005
05-04AU	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Australia	2006269251	01/09/2008
05-04CA	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Canada		01/08/2008
05-04CN	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	China	200680033237.3	03/11/2008
05-04EP	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	EPO	06786757.2	01/31/2008
05-04IL	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Israel	188448	12/27/2007
05-04IN	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	India		01/07/2008
05-04JP	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Јарап	2008-521491	01/07/2008
05-04KR	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Korea	10-2008-7003354	02/11/2008
05-04MX	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Mexico	MX/a/2008/000600	01/11/2008
05-04NO	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Norway	20080713	02/11/2008
05-04NZ	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	New Zealand	564984	01/09/2008

05-04P1	FORMULATIONS FOR ENHANCED	US	60/698,052	07/11/2005	
03-0-11	MUCOSAL DELIVERY OF PYY		00/076,032		
05-04PCT	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	PCT	PCT/US2006/026707	07/10/2006	
05-04SG	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Singapore	200800148-9	01/08/2008	
05-04US	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	US	11/995,315	01/10/2008	
05-04ZA	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	South Africa	2008/00285	01/09/2008	
05-05P1	STABLE PYY DOSAGE FORMS FOR ENHANCED MUCOSAL DELIVERY	US	60/699,294	07/13/2005	
05-06P1	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION HAVING HIGH CONCENTRATIONS OF MELANOCORTIN-4 RECEPTOR AGONISTS	US	60/702,576	07/25/2005	
05-06PCT	THERAPEUTIC FORMULATION FOR TRANSMUCOSAL ADMINISTRATION OF A MELANOCORTIN-4 RECEPTOR AGONIST	PCT			
05-07AU	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Australia		02/27/2008	
05-07CA	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Canada		01/25/2008	
05-07CN	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	China		01/28/2008	
05-07CON	TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	12/108,452	04/23/2008	
05-07EP	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	ЕРО	06800560.2	02/26/2008	
05-07IN	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	India	9261/DELNP/2007	11/30/2007	
05-07JP	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Japan	2008-524269	01/16/2008	
05-07KR	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Republic of Korea	10-2008-7004636	02/26/2008	

05-07MX	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Mexico	MX/a/2008/001352	01/25/2008	
05-07NZ	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	New Zealand	566281	02/27/2008	
05-07P1	TIGHT JUNCTION MODULATOR PEPTIDE PN159 FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/703,291	07/27/2005	
05-07PCT	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	PCT	PCT/US2006/029768	07/27/2006	
05-07SG	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Singapore	200719086-1	12/28/2007	
05-07US	TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	us	11/233,239	09/21/2005	
05-07US2	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	us	11/997,132	01/28/2008	
05-08P1	PEGYLATION OF TIGHT JUNCTION MODULATOR PEPTIDES	US	60/703,289	07/27/2005	
05-09P1	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION THAT INCREASE MELANOCORTIN-4 RECEPTOR AGONIST BIOAVAILABILITY	us	60/707,667	08/12/2005	
05-09US	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION THAT INCREASE MELANOCORTIN-4 RECEPTOR AGONIST BIOAVAILABILITY	US	11/464,163	08/11/2006	
05-11P1	TIGHT JUNCTION MODULATING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	us	60/710,637	08/22/2005	
05-12P1	TIGHT JUNCTION MODULATING LIPIDS FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/722,334	09/30/2005	
05-12US	METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	11/536,937	09/29/2006	,
05-15P1	COMBINATION THERAPY FOR TREATING OSTEOPOROSIS BY INTRANASAL DELIVERY OF PTH(1-34) (TERIPARATIDE)	us	60/730,547	10/25/2005	

	A COMPLANT TO DESCRIPTION OF THE PROPERTY OF T		T	1005000	
	METHOD FOR TREATING OSTEOPOROSIS			10/25/2006	
05-15US	BY INTRANASAL DELIVERY OF	US	11/552,810		
00 10 00	TERIPARATIDE WITH AN ANTI-	,	11.002,010		
	RESORPTIVE AGENT				
	COMPOSITIONS AND USE FOR				
05-19AU	INTRANASAL ADMINISTRATION OF	Australia			
	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			04/16/2008	
05-19CA	INTRANASAL ADMINISTRATION OF	Canada			
	RAPID ACTING INSULIN		1 ·		
	COMPOSITIONS AND USE FOR			06/19/2008	
05-19CN	INTRANASAL ADMINISTRATION OF	China			
	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			04/15/2008	
05-19EP	INTRANASAL ADMINISTRATION OF	EPO	06826368.0		
05 1721	RAPID ACTING INSULIN		00020300.0		
	COMPOSITIONS AND USE FOR			04/14/2008	
05-19IL		190838	0 11 11 2000		
05-1711	RAPID ACTING INSULIN	151 401	120030		
	COMPOSITIONS AND USE FOR			04/17/2008	· · · · · ·
05-19IN	INTRANASAL ADMINISTRATION OF	India		04/1//2006	
03-19114	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			04/15/2008	
05 10TD	l .	Y		04/15/2008	
05-19JP	INTRANASAL ADMINISTRATION OF	Japan			
	RAPID ACTING INSULIN			05/10/0000	
0 = 40***	COMPOSITIONS AND USE FOR	Republic of	40,000, =0440=0	05/19/2008	
05-19KR	INTRANASAL ADMINISTRATION OF	Korea	10-2008-7011970		
	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			04/17/2008	
05-19MX	INTRANASAL ADMINISTRATION OF	Mexico	MX/a/2008/004980		
	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			05/16/2008	
05-19NZ	INTRANASAL ADMINISTRATION OF	New Zealand	568357		
	RAPID ACTING INSULIN				
05-19P1	INTRANASAL ADMINISTRATION OF	US	60/728,877	10/20/2005	
03-1911	INSULIN	03	00/728,877		
	COMPOSITIONS AND USE FOR			10/20/2006	
05-19PCT	INTRANASAL ADMINISTRATION OF	PCT	PCT/US2006/041081		
	RAPID ACTING INSULIN				
	COMPOSITIONS AND USE FOR			04/14/2008	
05-19SG	INTRANASAL ADMINISTRATION OF	Singapore	200802830-0		
	RAPID ACTING INSULIN	0 1			
	COMPOSITIONS AND USE FOR			05/19/2008	
05-19ZA	INTRANASAL ADMINISTRATION OF	South Africa	2008/04287		
05 15241	RAPID ACTING INSULIN		2000/0120/		
	TRANSMUCOSAL DELIVERY OF			12/09/2005	
	MELANOCORTIN-4 RECEPTOR AGONIST	•		1210712003	
05-22P1	PEPTIDE CONJUGATED WITH WATER-	US	60/748,946		
UJ-22F I	SOLUBLE POLYMERS IN THE PRESENCE	US	00//40,340		
	OF PERMEATION ENHANCERS	·		11/17/2005	
05 0051	COMPOSITION FOR ENHANCED	TŤO	(0/700 064	11/17/2005	
05-23P1	MUCOSAL DELIVERY OF	ÚS	60/738,264		
	PARATHYROID HORMONE		<u> </u>	<u> </u>	

	METHOD OF MODULATING		<u> </u>	11/18/2005	
				11/18/2005	
05.0471	HEMATOPOIETIC STEM CELLS AND	710	60/700 004		
05-24P1	TREATING HEMATOLOGIC DISEASES	US	60/738,224		
	USING INTRANASAL PARATHYROID				
	HORMONE				
	METHOD OF MODULATING			11/13/2006	
	HEMATOPOIETIC STEM CELLS AND				
05-24US	TREATING HEMATOLOGIC DISEASES	US	11/559,276	•	
	USING INTRANASAL PARATHYROID				
	HORMONE				
	TIGHT JUNCTION MODULATING			12/16/2005	
OF 22D1	PEPTIDES FOR ENHANCED MUCOSAL	TIC	60/750 006		
05-32P1	DELIVERY OF THERAPEUTIC	US .	60/750,886		
	COMPOUNDS				
	TIGHT JUNCTION MODULATING	•		12/15/2006	
	PEPTIDES FOR ENHANCED MUCOSAL				
05-32US	DELIVERY OF THERAPEUTIC	US	11/611,289		
	COMPOUNDS		·		
	INTRANASAL PYY FORMULATIONS			12/19/2005	
05-33P1	WITH IMPROVED TRANSMUCOSAL	US	60/751,598	12/13/2003	
05-5511	PHARMACOKINETICS		00/751,596		
	INTRANASAL PYY FORMULATIONS			12/19/2006	
OF POTTS	WITH IMPROVED TRANSMUCOSAL	TTO	11/612 100	12/19/2006	
05-33US		US	11/613,109		
	PHARMACOKINETICS ENHANCED MICCORAL ADMINISTRATION			10/00/0005	
05-34P1	ENHANCED MUCOSAL ADMINISTRATION	US	60/753,968	12/23/2005	
	OF NEUROPROTECTIVE PEPTIDES		ļ		
05-34US	ENHANCED MUCOSAL ADMINISTRATION	US	11/614,534	12/21/2006	•
	OF NEUROPROTECTIVE PEPTIDES		<u> </u>		
	TIGHT JUNCTION MODULATING LIPIDS	US 60/760,815	01/20/2006		
06-01P1	FOR ENHANCED MUCOSAL DELIVERY				
	OF THERAPEUTIC COMPOUNDS				
	METHOD OF INCREASING			02/10/2006	
06-03P1	BIOAVAILABILITY OF A DRUG USING	US	60/772,435		
00-0311	PEGYLATED TIGHT JUNCTION	03	00/1/2,433		
	MODULATOR PEPTIDES				
	A METHOD OF ENHANCING			02/10/2006	
06-04P1	TRANSMUCOSAL DELIVERY OF	US	60/772,311		
	THERAPEUTIC COMPOUNDS				
06.0771	INTRANASAL ADMINISTRATION OF	***	60/220 204	03/03/2006	
06-07P1	RAPID ACTING INSULIN	US	60/778,724		
	THERAPEUTIC FORMULATIONS FOR		<u> </u>	03/03/2006	
	TRANSMUCOSAL ADMINISTRATION				
06-08P1	HAVING HIGH CONCENTRATIONS OF	US	60/778,681		-
00 001 1	AMPA RECEPTOR REGULATING	0.5	00,770,001		
	COMPOUNDS				
	A METHOD FOR IMPROVED PEPTIDE IN-			04/27/2006	
06-09P1	USE STABILITY	US	60/796,273	04/2//2000	
	COMPOSITIONS AND METHODS FOR			12/20/2006	
	ENHANCED CALORIC INTAKE			12/20/2000	
06-12P1	REDUCTION AND METHODS FOR	US	60/871,092		
	1				
	TREATING AND PREVENTING OBESITY			07/10/2026	
06-13E1	INTRANASAL ADMINISTRATION OF A	US	11/456,176	07/10/2006	
	RAPID ACTING INSULIN FORMULATION	_		0.5 (
06-13P1	INTRANASAL ADMINISTRATION OF A	US	60/806,904	07/10/2006	
00 101 A	RAPID ACTING INSULIN FORMULATION		30,000,001	1	

06-19P1	PTH FORMULATIONS FOR INTRANASAL DELIVERY	US	60/806,760	07/07/2006
06-19US	PTH FORMULATIONS FOR INTRANASAL DELIVERY	US	11/774,501	07/06/2007
06-24P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/804,165	06/07/2006
06-26P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/806,230	06/29/2006
06-26P2	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/807,055	07/11/2006
06-26P3	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/825,090	09/08/2006
06-26PCT	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	PCT	PCT/US2007/060517	01/12/2007
06-28P1	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	UŠ	60/821,525	08/04/2006
06-28P2	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/825,876	09/15/2006
06-28P3	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/868,703	12/05/2006
06-28P4	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/894,130	03/09/2007
06-28PCT	COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF	PCT	PCT/US2007/67007	04/19/2007
06-29P1	PTH FORMULATIONS AND METHODS OF USE	US	60/871,633	12/22/2006
06-29P2	VISCOSITY ENHANCED PTH FORMULATIONS AND IONIC POLYMER- PTH SUSPENSIONS AND METHODS OF USE	US	60/945,867	06/22/2007
06-29P3	IONIC POLYMER-PTH SUSPENSIONS WITHIN A REVERSIBLE GEL MATRIX AND METHODS OF USE	US	60/947,362	06/29/2007
07-05P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/891,204	02/22/2007
07-05P2	PHARMACEUTICAL FORMULATIONS FOR INTRANASAL DELIVERY OF GLP-1 DERIVATIVES	US	60/944,397	06/15/2007
07-05P3	FORMULATIONS FOR DELIVERY OF GLP- 1 DERIVATIVES AND USES THEREOF	US	61/015,036	12/19/2007
07-06P1	METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/909,333	03/30/2007
07-07P1	GLP-1 ANALOGS, DERIVATIVES AND USE THEREOF	US	60/911,249	04/11/2007
07-07US	PHARMACEUTICAL FORMULATIONS FOR INTRANASAL DELIVERY OF GLP-1 ANALOGS, DERIVATIVES AND USE THEREOF	US	11/841,697	08/20/2007
07-08P1	COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/910,388	04/05/2007

	STABLE PEPTIDES AND PROTEINS AND			04/26/2007	т
07-09P1	METHODS FOR REDUCING	US	60/914,247	04/20/2007	
07-0911	DEAMIDATION	US	00/914,247		
	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2)			04/03/2007	
07-11P1	ANALOGUES AND METHODS OF USE	US	60/909,757	04/05/2007	
	INTRANASAL CARBETOCIN			06/07/2007	
07-13P1	FORMULATIONS AND METHODS FOR	. US	60/942,607	00/07/2007	
07-1511	TREATMENT OF AUTISM	. 03	00/942,007		
	ULTRA-RAPID ACTING INTRANASAL			06/08/2007	-
07-14P1	MONOMER/DIMER STABILIZED INSULIN	US	60/942,981	00/06/2007	i
07-1411	FORMULATIONS	O ₂	00/342,701		
	PHARMACOKINETIC-			08/10/2007	
	PHARMACODYNAMIC RELATIONSHIP			06/10/2007	*
07-14P2	FOR ULTRA-RAPID ACTING	US	60/955,306		
	INTRANASAL INSULIN FORMULATIONS				
	INSULIN DOSAGE FORM FOR ULTRA-			12/21/2007	
07-14P3	RAPID ACTING INTRANASAL INSULIN	US	61/016,383	12/21/2007	
07-14P3		03	01/010,363		
	FORMULATIONS INSULIN DOSAGE FORM FOR ULTRA-			09/20/2007	
07 14110	1	TIC	11/0/1 400	08/20/2007	
07-14US	RAPID ACTING INTRANASAL INSULIN	US	11/841,688		
	FORMULATIONS FORMULATIONS			10/05/2007	
07-18P1	FORMULATIONS FOR INTRANASAL	US	60/977,848	10/05/2007	
	DELIVERY OF DIAZEPAM		· · · · · · · · · · · · · · · · · · ·	10/05/0007	
07 1000	FORMULATIONS FOR INTRANASAL	110	(0/000 (00	10/25/2007	
07-18P2	18P2 DELIVERY OF DIAZEPAM AND USE US 60/982,680 THEREOF	60/982,680			
				11/06/0007	<u> </u>
07.1002	MULTI-COMPONENT FORMULATIONS		60/005 019	11/06/2007	
07-18 P 3	FOR INTRANASAL DELIVERY OF	US	60/985,918		
	DIAZEPAM AND USE THEREOF			11/20/2007	
07-18P4	MULTI-COMPONENT DIAZEPAM	US	60/989,370	11/20/2007	
	FORMULATIONS AND USES THEREOF		<u> </u>	01/11/0000	_
07.1007	MULTI-COMPONENT FORMULATIONS	7.10	(1/000 (60	01/11/2008	
07-18P5	FOR ADMINISTRATION OF DIAZEPAM	·US	61/020,668		
	AND USES THEREOF			00/11/0007	-
07-20P1	POLYMER DELIVERY COMPOSITIONS	US	60/971,488	09/11/2007	
	AND METHODS OF USE THEREOF		<u> </u>	11/14/2007	-
07-25P1	MUCOSAL DELIVERY OF FACTOR IX	US	60/988,036	11/14/2007	
	AND USES THEREOF	7.70	61/055.150	05/00/0000	
08-01P1	LIPOPHILIC AMINES AND USES THEREOF	US	61/057,153	05/29/2008	
	STABLE PEPTIDES AND PROTEINS AND		601045 406	04/23/2008	
08-05P1	METHODS FOR REDUCING	US	60/047,136	-	
	DEAMIDATION			0.12911000	
	METHOD OF ADMINISTERING NARCOTIC			04/27/1982	1,183,778
81-01CA	ANTAGONISTS AND ANALGESICS AND	Canada	401,775		
01 01	NOVEL DOSAGE FORMS CONTAINING		,		
· · · · · · · · · · · · · · · · · · ·	SAME			0.4/20011111	
	METHOD OF ADMINISTERING NARCOTIC			04/27/1982	
81-01PCT	ANTAGONISTS AND ANALGESICS AND	PCT	PCT/US82/00546		
01 011 01	NOVEL DOSAGE FORMS CONTAINING	101	101,0502,000 10		
	SAME				
	METHOD OF ADMINISTERING NARCOTIC			04/28/1981	4,464,378
81-01US	ANTAGONISTS AND ANALGESICS AND	US	06/258,308		
01-0100	NOVEL DOSAGE FORMS CONTAINING	55	00,200,000		
	SAME				

<u>-</u>	NOVEL METHOD OF ADMINISTERING			10/22/1985	E75400
	ANTI-NAUSEA AND ANTI-EMETIC			·	
84-01AT	PHARMACEUTICAL AGENTS AND	Austria	85905471		
	NOVEL DOSAGE FORMS CONTAINING				
	SAME				
84-01AU2	ANTI-NAUSEA AND ANTI-EMETIC	Australia	15061/88	04/21/1988	596741
04-01AO2	AGENTS	Australia	13001/66		
	NOVEL METHOD OF ADMINISTERING			10/22/1985	0201537
	ANTI-NAUSEA AND ANTI-EMETIC				
84-01BE	PHARMACEUTICAL AGENTS AND	Belgium	85905471.0		
	NOVEL DOSAGE FORMS CONTAINING				
	SAME			_	
	METHOD OF ADMINISTERING ANTI-			10/23/1985	1265056
•	NAUSEA AND ANTI-EMETIC				
84-01CA	PHARMACEUTICAL AGENTS AND	Canada	493629		
	NOVEL DOSAGE FORMS CONTAINING				
	SAME				
	METHODS OF ADMINISTERING	•	•	05/05/1988	1309023
	ANTIHISTAMINES, ANTINAUSEA AND				
84-01CA2	ANTIEMETIC PHARMACEUTICAL	Canada	565963		
	AGENTS AND NOVEL DOSAGE FORMS		k		
	CONTAINING SAME				
	NOVEL METHOD OF ADMINISTERING			10/22/1985	201537
	ANTI-NAUSEA AND ANTI-EMETIC	Switzerland and			
84-01CH	PHARMACEUTICAL AGENTS AND	Liechtens	85905471		
	NOVEL DOSAGE FORMS CONTAINING	Licentens			
	SAME				
	NOVEL METHOD OF ADMINISTERING		,	11/15/1984	
	ANTI-NAUSEA AND ANTI-EMETIC				
84-01CIP	PHARMACEUTICAL AGENTS AND	US	06/671,694		
	NOVEL DOSAGE FORMS CONTAINING				
	SAME	<u> </u>			
	NOVEL METHOD OF ADMINISTERING	1		10/22/1985	
0.4.04.07.04.17	ANTI-NAUSEA AND ANTI-EMETIC		50500105		,
84-01CIP/AU	PHARMACEUTICAL AGENTS AND	Australia	50638/85		
	NOVEL DOSAGE FORMS CONTAINING				
	SAME			10/00/1005	
	NOVEL METHOD OF ADMINISTERING			10/22/1985	
0.4.01(777)	ANTI-NAUSEA AND ANTI-EMETIC	D:1	D10507000		
84-01CIP/BR	PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING	Brazil	P18507008		
	SAME				ŀ
	NOVEL METHOD OF ADMINISTERING			10/15/1985	4,624,965
	ANTI-NAUSEA AND ANTI-EMETIC			10/13/1903	4,024,905
94 01CTD2	PHARMACEUTICAL AGENTS AND	us	06/787,617		
84-01CIP2	NOVEL DOSAGE FORMS CONTAINING	03	00/767,017		
	SAME				
		1-		08/19/1986	4,729,997
	I NOVEL METHOD OF ADMINISTEDING				
	NOVEL METHOD OF ADMINISTERING MECHIZINE TYPE PHARMACEUTICAL		•	06/19/1960	7,129,991
84-01CIP2/DIV	MOVEL METHOD OF ADMINISTERING MECLIZINE TYPE PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS	US	06/897,863	08/19/1980	7,129,991

84-	NOVEL METHOD OF ADMINISTERING ANTIHISTAMINES, ANTINAUSEA AND			04/24/1987	4,749,700
01CIP2DIVCI P	ANTIEMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	07/042,386		
84-01DE	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Germany	85905471.0	10/22/1985	P358595
84-01EP	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	EPO	85905471	10/22/1985	201537
84-01FR	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	France	85905471	10/22/1985	201537
84-01GB	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	United Kingdom	85905471.0	10/22/1985	201537
84-01IT	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Ítaly	85905471.0	10/22/1985	201537
84-01JP	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Japan	504814/85	10/22/1985	1993603
84-01LU	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Luxembourg	85905471	10/22/1985	201537
84-01NL	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Netherlands	85905471	10/22/1985	201537
84-01P1	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/663,894	10/23/1984	
84-01PCT	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	PCT	PCT/US85/02071	10/22/1985	

	NOVEL METHOD OF ADMINISTERING	T		10/22/1985	201537
	ANTI-NAUSEA AND ANTI-EMETIC	ľ		10/22/1965	201337
84-01SE	PHARMACEUTICAL AGENTS AND	Sweden	85905471		
04 015L	NOVEL DOSAGE FORMS CONTAINING	S WOODIN	, 05/05471	,	
	SAME			·	
	NOVEL METHOD OF ADMINISTERING			12/07/1984	
84-02CIP	TESTOSTERONE AND NOVEL DOSAGE	US	06/679,553	12/0//1904	
64-02CIP	FORMS CONTAINING SAME	08	00/0/9,333		
				02/11/1002	(2000)
92-01AT	SELF-ASSEMBLING DIKETOPIPERAZINE	Austria	93920574.6	03/11/1993	630236
	DRUG DELIVERY SYSTEM			00/44/4000	100100
92-01AU	SELF-ASSEMBLING DIKETOPIPERAZINE	Australia	38044/93	03/11/1993	680408
	DRUG DELIVERY SYSTEM				
'92-01BE	SELF-ASSEMBLING DIKETOPIPERAZINE	Belgium	93920574.6	03/11/1993	630236
	DRUG DELIVERY SYSTEM				
92-01CA	SELF-ASSEMBLING DIKETOPIPERAZINE	Canada	N/A	03/11/1993	1
)2-01CH	DRUG DELIVERY SYSTEM				
92-01CH	SELF-ASSEMBLING DIKETOPIPERAZINE	Switzerland and	93920574.6	03/11/1993	630236
92-01CH	DRUG DELIVERY SYSTEM	Liechtens	93920374.0		1
02.01DE	SELF-ASSEMBLING DIKETOPIPERAZINE	Cammanu	02020574.6	03/11/1993	630236
92-01DE	DRUG DELIVERY SYSTEM	Germany	93920574.6		
00.01DI	SELF-ASSEMBLING DIKETOPIPERAZINE	D 1	00000554.6	03/11/1993	630236
92-01DK	DRUG DELIVERY SYSTEM	Denmark	93920574.6		
22 2477	SELF-ASSEMBLING DIKETOPIPERAZINE	7770	00000000	03/11/1993	630236
92-01EP	DRUG DELIVERY SYSTEM	EPO	93920574.6	10,11,122	323223
	SELF-ASSEMBLING DIKETOPIPERAZINE			03/11/1993	630236
92-01ES	DRUG DELIVERY SYSTEM	Spain	93920574.6	05,11,15,5	050250
	SELF-ASSEMBLING DIKETOPIPERAZINE			03/11/1993	630236
92-01FR	DRUG DELIVERY SYSTEM	France	93920574.6	03/11/17/3	050250
	SELF-ASSEMBLING DIKETOPIPERAZINE			03/11/1993	630236
92-01GB	DRUG DELIVERY SYSTEM	United Kingdom	93920574.6	03/11/1993	030230
	SELF-ASSEMBLING DIKETOPIPERAZINE			03/11/1993	630236
92-01GR	DRUG DELIVERY SYSTEM	Greece	93920574.6	03/11/1993	030230
	SELF-ASSEMBLING DIKETOPIPERAZINE			03/11/1993	630236
92-01 I E		Ireland	93920574.6	03/11/1993	030230
	DRUG DELIVERY SYSTEM SELF-ASSEMBLING DIKETOPIPERAZINE	ļ		02/11/1002	0617070
92-01 JP		Japan	5-516624	03/11/1993	2617273
	DRUG DELIVERY SYSTEM			00/11/1000	100000
92-01LU	SELF-ASSEMBLING DIKETOPIPERAZINE	Luxembourg	93920574.6	03/11/1993	630236
	DRUG DELIVERY SYSTEM				
92-01MC	SELF-ASSEMBLING DIKETOPIPERAZINE	Monaco	93920574.6	03/11/1993	630236
	DRUG DELIVERY SYSTEM				
92-01NL	SELF-ASSEMBLING DIKETOPIPERAZINE	Netherlands	93920574.6	03/11/1993	630236
<u> </u>	DRUG DELIVERY SYSTEM	1100110111015	75720571.0		
92-01PT	SELF-ASSEMBLING DIKETOPIPERAZINE	Portugal	93920574.6	03/11/1993	630236
92-011 1	DRUG DELIVERY SYSTEM	1 Ortugar	73920374.0		
92-01SE	SELF-ASSEMBLING DIKETOPIPERAZINE	Sweden	93920574.6	03/11/1993	630236
92-013E	DRUG DELIVERY SYSTEM	Sweden	93920374.0		
	INTRANASAL FORMULATIONS FOR			09/29/1997	
96-02AT	PROMOTING SLEEP AND METHOD OF	Austria	97944550.9		
	USING THE SAME				
	INTRANASAL FORMULATIONS FOR			09/29/1997	714913
96-02AU	PROMOTING SLEEP AND METHOD OF	Australia	46019/97		
, C 02210	USING THE SAME		.0015/7/		
	INTRANASAL FORMULATIONS FOR			09/29/1997	+
96-02BE	PROMOTING SLEEP AND METHOD OF	Belgium	97944550.9	0312311331	
30-02DE	USING THE SAME	Deigium	フィフササンンひ・フ	}	
	L OOTHO TITE DUME	<u> </u>			

96-02CA	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF	Canada	2,266,898	09/29/1997	
90-02CA	USING THE SAME	Canada	2,200,696		
96-02EP	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF	EPO	97944550.9	04/26/1999	
	USING THE SAME				
96-02JP	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Japan	10-515992	09/29/1997	
96-02P	DOXYLAMINE SUCCINATE FORMULATION DEVELOPMENT FIRST LINE OF FORMULATIONS FOR HUMAN STUDIES	US	60/026,811	09/27/1996	
96-02PCT	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	PCT	PCT/US97/17475	09/29/1997	
96-02US	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	US	08/939,279	09/29/1997	5,874,450
96-03AU	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	Australia	54294/98	11/04/1997	725498
96-03CA	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	CANADA	2,271,724	11/04/1997	
96-03EP	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	EPC	97948175.1	11/04/1997	
96-03JP	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	Japan	10-522637	05/12/1999	
96-03PCT	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	PCT	PCT/US97/20115	11/04/1997	
96-03US	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	US	08/748,356	11/13/1996	5,770,618
9 7-01AT	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Austria	98946945.7	09/11/1998	
97-01AU	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Australia	93850/98	09/11/1998	742878
97-01BE	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Belgium	98946945.7	09/11/1998	

	INTRANASAL FORMULATIONS			09/11/1998	2,303,132
97-01 CA	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Canada	2,303,132		
	INTRANASAL FORMULATIONS			09/11/1998	
97-01CH	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Switzerland and Liechtens	98946945.7	09/11/1996	
	INTRANASAL FORMULATIONS			09/11/1998	-
97-01DE	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Germany	98946945.7		
	INTRANASAL FORMULATIONS			09/11/1998	
97-01DK	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Denmark	98946945.7		
	INTRANASAL FORMULATIONS			09/11/1998	
97-01EP	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	EPO	98 946 945.7-2123		
	INTRANASAL FORMULATIONS			09/11/1998	
97-01ES	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Spain	98946945.7		ż
	INTRANASAL FORMULATIONS			09/11/1998	
97-01FI	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Finland	98946945.7		
97-01FR	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	France	98946945.7	09/11/1998	
	INTRANASAL FORMULATIONS			09/11/1998	
97-01GB	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	United Kingdom	98946945.7	03/11/1998	
	INTRANASAL FORMULATIONS		•	09/11/1998	
97-01GR	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Greece	98946945.7		
*	INTRANASAL FORMULATIONS			09/11/1998	
97-01IE	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Ireland	98946945.7		
	INTRANASAL FORMULATIONS		09/11/19	09/11/1998	
97-01IT	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Italy	98946945.7		
	INTRANASAL FORMULATIONS			09/11/1998	
97-01JP	CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Japan	2000-510441		

	INTRANASAL FORMULATIONS			00/11/1009			
	CONTAINING SCOPOLAMINE AND			09/11/1998			
97-01LU	METHOD OF TREATING MOTION	Luxembourg	Luxembourg	Luxembourg	98946945.7		
	SICKNESS						
	INTRANASAL FORMULATIONS			09/11/1998			
	CONTAINING SCOPOLAMINE AND			05/11/1556			
97-01 MC	METHOD OF TREATING MOTION	Monoco	98946945.7				
	SICKNESS						
	INTRANASAL FORMULATIONS			09/11/1998			
07.0437	CONTAINING SCOPOLAMINE AND		00045047	0,,12,,2,,0			
97-01NL	METHOD OF TREATING MOTION	Netherlands	98946945.7				
	SICKNESS						
	INTRANASAL FORMULATIONS			09/11/1997			
97-01P	CONTAINING SCOPOLAMINE AND	ÜS	60/058,651				
9/-UIF	METHOD OF TREATING MOTION	US	00/038,031				
	SICKNESS						
	INTRANASAL FORMULATIONS			09/11/1998			
97-01PCT	CONTAINING SCOPOLAMINE AND	PCT	PCT/US98/18953				
)/**OII CI	METHOD OF TREATING MOTION	101	101/00/0/10/55				
	SICKNESS						
	INTRANASAL FORMULATIONS		•	09/11/1998			
97-01PT	CONTAINING SCOPOLAMINE AND	Portugal	98946945.7	*			
,	METHOD OF TREATING MOTION						
	SICKNESS NUMBER AND SALE FORMULA ATTOMIC			00/11/1000	-		
	INTRANASAL FORMULATIONS		•	09/11/1998			
97-01SE	CONTAINING SCOPOLAMINE AND	Sweden	98946945.7				
	METHOD OF TREATING MOTION SICKNESS						
	INTRANASAL FORMULATIONS			03/01/2000			
	CONTAINING SCOPOLAMINE AND			03/01/2000			
97-01US2	METHOD OF TREATING MOTION	US	09/486,839				
	SICKNESS						
	NASAL DELIVERY OF SILDENAFIL		60,000,014	06/26/1998			
98-01 P1	CITRATE	US	60/090,941				
00.01000	NASAL DELIVERY OF SILDENAFIL	nam	DCTT#1000/14070	06/24/1999			
98-01PCT	CITRATE	PCT	PCT/US99/14352		•		
98-02P1	METHODS OF PREVENTING AND	US	60/091,114	06/29/1998	···		
96-0211	TREATING MOTION SICKNESS	0.5	00/091,114				
98-02PCT	METHODS OF PREVENTING AND	PCT	PCT/US99/14657	06/29/1999			
	TREATING MOTION SICKNESS						
98-03AT	NASAL DELIVERY OF APOMORPHINE	Austria	914639	02/18/2000			
98-03AU	NASAL DELIVERY OF APOMORPHINE	Australia	36,002/00	02/18/2000			
98-03BE	NASAL DELIVERY OF APOMORPHINE	Belgium	914639	02/18/2000			
98-03BR	NASAL DELIVERY OF APOMORPHINE	Brazil	PI0012080.4	02/18/2000			
98-03BZ	NASAL DELIVERY OF APOMORPHINE	Belize	2 276 021	02/19/2022			
98-03CA	NASAL DELIVERY OF APOMORPHINE NASAL DELIVERY OF APOMORPHINE	Canada	2,376,921	02/18/2000 06/11/2001			
98-03CIP2	FOR YIELDING ENHANCED NASAL	US	09,882,746	00/11/2001			
90-03CH 2	ABSORPTION	03	09,002,740				
	NASAL DELIVERY OF APOMORPHINE IN			09/19/2000			
98-03CIP3	COMBINATION WITH GLYCOL	US	09/665,500	37,17,2000			
, o obom b	DERIVATIVES		37.005,000				
	NASAL DELIVERY OF APOMORPHINE IN			09/19/2001			
~~	,						
98- 03CIP3/PCT	COMBINATION WITH GLYCOL	PCT	PCT/US01/29437				

98-03CO	NASAL DELIVERY OF APOMORPHINE	Colombia		T	1
98-03CON1	NASAL DELIVERY OF APOMORPHINE	US	10/062,020	01/31/2002	
98-03CON1 98-03CON2	NASAL DELIVERY OF APOMORPHINE	US		01/31/2002	6,740,660
		US	10/062,021 10/062,290	01/31/2002	0,740,000
98-03CON3	NASAL DELIVERY OF APOMORPHINE	03	10/002,290		
00.000000	NASAL DELIVERY OF APOMORPHINE IN	110	10/701 05/	11/05/2003	
98-03CON5	COMBINATION WITH GLYCOL	US	10/701,956		1.
00.00.000	DERIVATIVES	770	10/000 051	04/01/0004	
98-03CON6	NASAL DELIVERY OF APOMORPHINE	US	10/830,251	04/21/2004	
98-03CON7	NASAL DELIVERY OF APOMORPHINE	US	10/830,250	04/21/2004	
98-03CON8	NASAL DELIVERY OF APOMORPHINE	US	10/830,255	04/21/2004	
98-03CON9	NASAL DELIVERY OF APOMORPHINE	US	10/830,309	04/21/2004	
98-03CR	NASAL DELIVERY OF APOMORPHINE	Costa Rica	6521	12/04/2001	
98-03CY	NASAL DELIVERY OF APOMORPHINE	Cyprus	914639	02/18/2000	
98-03DE	NASAL DELIVERY OF APOMORPHINE	Germany	914639	02/18/2000	
98-03DK	NASAL DELIVERY OF APOMORPHINE	Denmark	914639	02/18/2000	
98-03EC	NASAL DELIVERY OF APOMORPHINE	Ecuador			
98-03EP	NASAL DELIVERY OF APOMORPHINE	EPO	00914639.0-2123	02/18/2000	
98-03EPDIV	NASAL DELIVERY OF APOMORPHINE	EPO	04028289.9	11/30/2004	
98-03FI	NASAL DELIVERY OF APOMORPHINE	Finland	914639	02/18/2000	
98-03FR	NASAL DELIVERY OF APOMORPHINE	France	914639	02/18/2000	
98-03GB	NASAL DELIVERY OF APOMORPHINE	United Kingdom	914639	02/18/2000	
98-03GR	NASAL DELIVERY OF APOMORPHINE	Ireland	914639	02/18/2000	
98-03JP	NASAL DELIVERY OF APOMORPHINE	Japan	2001-502842	02/18/2000	
	NASAL DELIVERY OF APOMORPHINE	Republic of		02/18/2000	
98-03KR		Korea	2001-7016072	02,10,200	
98-03MX	NASAL DELIVERY OF APOMORPHINE	Mexico	2001-012877	02/18/2000	
98-03NZ	NASAL DELIVERY OF APOMORPHINE	New Zealand	515782	02/18/2000	
98-03NZ2	NASAL DELIVERY OF APOMORPHINE	New Zealand	529954	12/04/2003	
98-03P1	NASAL DELIVERY OF APOMORPHINE	US	60/096,545	08/14/1998	
98-03PCT	NASAL DELIVERY OF APOMORPHINE	PCT	PCT/US00/04268	02/18/2000	
98-03US	NASAL DELIVERY OF APOMORPHINE	US	09/334,304	06/16/1999	6,436,950
98-04P1	NASAL DELIVERY OF XYLITOL	US	60/106,388	10/30/1998	
99-01AL	COMPOSITIONS AND METHODS	Albania	932722.2	05/23/2000	
99-01AL	COMPRISING MORPHINE GLUCONATE	Alballia	932122.2		
99-01AT	COMPOSITIONS AND METHODS	Austria	932722.2	05/23/2000	
99-01A1	COMPRISING MORPHINE GLUCONATE	Austria	932122,2		
00.01.477	COMPOSITIONS AND METHODS	Australia	50405/00	05/23/2000	775,112
99-01AU	COMPRISING MORPHINE GLUCONATE	Australia	30403700		-
99-01BE	COMPOSITIONS AND METHODS	Doloium	932722.2	05/23/2000	
99-01DE	COMPRISING MORPHINE GLUCONATE	Belgium	932122.2		
00.01BB	COMPOSITIONS AND METHODS	Descil	PI 0012081-2	05/23/2000	
99-01BR	COMPRISING MORPHINE GLUCONATE	Brazil	P1 0012081-2		
00.01.04	COMPOSITIONS AND METHODS	· Canada	2276 865	12/11/2001	
99-01CA	COMPRISING MORPHINE GLUCONATE	Canada	2,376,865		
00.01.077	COMPOSITIONS AND METHODS	Switzerland and	000700.0	05/23/2000	
99-01CH	COMPRISING MORPHINE GLUCONATE	Liechtens	932722.2		
00.01.001	COMPOSITIONS AND METHODS	110	00/606 040	10/19/2000	6,451,848
99-01CON	COMPRISING MORPHINE GLUCONATE	US	09/626,942		
00 01 577	COMPOSITIONS AND METHODS		000700	05/23/2000	-
99-01 CY	COMPRISING MORPHINE GLUCONATE	Cyprus	932722.2	,	
00.0177	COMPOSITIONS AND METHODS		0000000	05/23/2000	
99-01DE	COMPRISING MORPHINE GLUCONATE	Germany	932722.2		
00.61777	COMPOSITIONS AND METHODS	.	000700.0	05/23/2000	
99-01DK	COMPRISING MORPHINE GLUCONATE	Denmark	932722.2		
L				<u> </u>	

99-01EP	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	ЕРО	00932722.2	05/23/2000	
99-01FI	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Finland	932722.2	05/23/2000	
99-01FR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	France	932722.2	05/23/2000	
99-01GB	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	United Kingdom	932722.2	05/23/2000	
99-01GR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Greece	932722.2	05/23/2000	
99-01IE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Ireland	932722.2	05/23/2000	
99-01IT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Italy	932722.2	05/23/2000	
99-01JP	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Japan	2001-502671	05/23/2000	
99-01KR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Republic of Korea	2001-7016073	11/13/2001	
99-01LT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Lithuania	932722.2	05/23/2000	
99-01LU	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Luxembourg	932722.2	05/23/2000	
99-01MC	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Monoco	932722.2	05/23/2000	
99-01 M X	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Mexico	2001-012882	05/23/2000	5
99-01NL	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Netherlands	932722.2	05/23/2000	
99-01NZ	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	New Zealand	515781	05/23/2000	515781
99-01PCT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	PCT	PCT/US00/14150	05/23/2000	
99-01PT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Portugal	932722.2	05/23/2000	:
99-01RO	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Romania	932722.2	05/23/2000	
99-01SE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Sweden	932722.2	05/23/2000	
99-01 SI	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Slovenia	932722.2	05/23/2000	
99-01US	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	US	09/334,344	06/16/1999	6,225,343
99-02AT	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Austria	A9104/2000	05/23/2000	
99-02AU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Australia	.51561/00	05/23/2000	774,175
99-02BA	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Bosnia and Herzegovina	BAP01950A	05/23/2000	
99-02BR	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Brazil	PI 0012082-0	05/23/2000	

PHARMACEUTICAL FORMULATIONS			05/23/2000	
AND METHODS COMPRISING	Bulgaria 106221	03/23/2000		
1	Duigana	100221		
			05/23/2000	2,374,877
	Canada	2 374 844	03/23/2000	2,374,077
	Canada	2,574,044		
			05/23/2000	
		2283/01	3372372000	
	Liechtens			
			05/23/2000	
AND METHODS COMPRISING	Czech Republic	PV 2001-4399		
INTRANASAL MORPHINE	•			
PHARMACEUTICAL FORMULATIONS		···	05/23/2000	
AND METHODS COMPRISING	Germany	10084709.9		
INTRANASAL MORPHINE				
METHODS COMPRISING INTRANASAL	TIO	00/504 016	06/15/2000	6,677,346
MORPHINE	US	09/594,916		
PHARMACEUTICAL FORMULATIONS				
AND METHODS COMPRISING	US			
INTRANASAL MORPHINE			·	
PHARMACEUTICAL FORMULATIONS			05/23/2000	
AND METHODS COMPRISING	Denmark	PA200101859		
INTRANASAL MORPHINE				1
PHARMACEUTICAL FORMULATIONS			05/23/2000	
AND METHODS COMPRISING	Estonia	0677/01PC		
INTRANASAL MORPHINE				
PHARMACEUTICAL FORMULATIONS				
	Estonia	P200300555		
		•	05/23/2000	
	EPO	00936212.0		
			05/23/2000	
	EPO	04001252.8		
	Spain	P200150086	05/23/2000	
			0.5.100.100.00	10001016
	177.1	20012462	05/23/2000	20012462
	Finland	20012462		
			05/02/0000	2267005
	TI : 1 IV: 1	01002027	05/23/2000	2367005
	Onited Kingdom	0128383.7		
		· · · · · · · · · · · · · · · · · · ·	09/02/2004	
•	IIona Vana		08/02/2004	
	nong Kong			
	· · · · · · · · · · · · · · · · · · ·		08/02/2004	
	Hong Kong	•	00/02/2004	
	Tiong Kong			
			08/02/2004	
AND METHODS COMPRISING	Hong Kong	04105666.8	00/02/2004	
INTRANASAL MORPHINE	TAOUS IZOUS	0.00000140	1	
	1		i .	
			05/23/2000	
PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING	Croatia	P20010926A	05/23/2000	
	INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS	INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING Germany 10084709.9 INTRANASAL MORPHINE INTRANASAL US 09/594,916 METHODS COMPRISING US 10084709.9 INTRANASAL MORPHINE INTRANASAL US 09/594,916 METHODS COMPRISING US INTRANASAL MORPHINE INTRANASAL MO	INTRANASAL MORPHINE

	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02HU	AND METHODS COMPRISING	Hungary	P0201856		
	INTRANASAL MORPHINE	, ,,,,,,	10201050		
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02IS	AND METHODS COMPRISING	Iceland	6202	03/23/2000	
99-0213	INTRANASAL MORPHINE	icciand	0202		
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
00.02TD		T	2001 502820	03/23/2000	
99-02JP	AND METHODS COMPRISING	Japan	2001-502839		
	INTRANASAL MORPHINE			05/00/2000	
00.00777	PHARMACEUTICAL FORMULATIONS	Republic of	2004 504 6000	05/23/2000	
99-02KR	AND METHODS COMPRISING	Korea	2001-7016009		
	INTRANASAL MORPHINE				1
	PHARMACEUTICAL FORMULATIONS			05/23/2000	4976
99-02LT	AND METHODS COMPRISING	Lithuania	2001-119		
	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS			05/23/2000	90859
99-02LU	AND METHODS COMPRISING	Luxembourg	90859		
	INTRANASAL MORPHINE				ĺ
	PHARMACEUTICAL FORMULATIONS			05/23/2000	12859
99-02LV	AND METHODS COMPRISING	Latvia	P-01-169		
	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02MK1	AND METHODS COMPRISING	Macedonia	P-20010120		
	INTRANASAL MORPHINE				
	USE OF MORPHINE OR A			11/13/2003	
	PHARMACEUTICALLY ACCEPTABLE			1	
99-02MK2	SALT THEREOF FOR MANUFACTURE OF				
	A NASAL PPHARMACEUTICAL	Macedonia	P-20030381		1
	FORMULATIONS FOR TREATMENT OF				
	PAIN				
	USE OF A BUFFER FOR MANUFACTURE			11/13/2003	-
99-02MK3	OF A NASAL FORMULATION FOR	Macedonia	P-20030382	11/13/2003	-
99-02NIKJ	INCREASE SOLUBILITY OF MORPHINE	waccooma .	1-20030362		
	PHARMACEUTICAL FORMULATIONS	1		05/23/2000	
99-02MX	AND METHODS COMPRISING	Mexico	2001-012879	03/23/2000	ļ
99-02IVIA	i I	MEXICO	2001-012679		İ
	INTRANASAL MORPHINE			05/02/0000	
00 0010	PHARMACEUTICAL FORMULATIONS	3.7 .	20015021	05/23/2000	
99-02NO	AND METHODS COMPRISING	Norway	20015931		
	INTRANASAL MORPHINE			07/00/0000	717700
	PHARMACEUTICAL FORMULATIONS		#4.#moo	05/23/2000	515783
99-02NZ	AND METHODS COMPRISING	New Zealand	515783		
	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02PCT	AND METHODS COMPRISING	PCT	PCT/US00/14157		
	INTRANASAL MORPHINE	· · · · · · · · · · · · · · · · · · ·			
*	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02PL	AND METHODS COMPRISING	Poland	P 352556		
	INTRANASAL MORPHINE	·			
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02PT	AND METHODS COMPRISING	Portugal	WO 00/76506	1	
¥	INTRANASAL MORPHINE			. L	
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
	1 III HUMI CEE TICHET CHUICE THE				
99-02RO	AND METHODS COMPRISING	Romania	2001-01346		

	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02SE	AND METHODS COMPRISING	Sweden	0104203-5	03/23/2000	·
99-025E	INTRANASAL MORPHINE	Sweden	0104203-3		
_	PHARMACEUTICAL FORMULATIONS			05/23/2000	20850
99-02SI	AND METHODS COMPRISING	Slovenia	P-200020030	03/23/2000	20830
99-0231	INTRANASAL MORPHINE	Siovenia	1-200020030		
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
00 02617		Claval Danublia	DX/1017 2001C	03/23/2000	
99-02SK	AND METHODS COMPRISING	Slovak Republic	PV1817-2001S		
	INTRANASAL MORPHINE			05/23/2000	<u> </u>
00.00	PHARMACEUTICAL FORMULATIONS	T1	0001/00/12	05/23/2000	
99-02TR	AND METHODS COMPRISING	Turkey	2001/03613		
	INTRANASAL MORPHINE			06/16/1000	-
	PHARMACEUTICAL FORMULATIONS		00/00/ 505	06/16/1999	
99-02US	AND METHODS COMPRISING	US	09/334,537		
	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
99-02YU	AND METHODS COMPRISING	Yugoslavia	N/A		
	INTRANASAL MORPHINE				
99-03PCT	METHODS AND COMPOSITIONS FOR	PCT	PCT/US00/14663	05/26/2000	
	TREATING BREAKTHROUGH PAIN				
99-03US	METHODS AND COMPOSITIONS FOR	US	09/334,303	06/16/1999	
	TREATING BREAKTHROUGH PAIN	00	07/354,503		-
	METHOD FOR INCREASING THE			07/28/2000	
99-04DIV	SOLUBILITY OF MORPHINE AND	US	09/627,598		
99-04D1V	PHARMACEUTICAL COMPOSITIONS		07/021,570		
	PREPARED THEREFROM				
4	METHOD FOR INCREASING THE			05/26/2000	
99-04PCT	SOLUBILITY OF MORPHINE AND	PCT	PCT/US00/14662		
99-0 4 1 C1	PHARMACEUTICAL COMPOSITIONS	101	1 C1/C300/14002		
	PREPARED THEREFROM	*			
	METHOD FOR INCREASING THE			06/16/1999	•
99-04US	SOLUBILITY OF MORPHINE AND	us	09/334,536		
99-0403	PHARMACEUTICAL COMPOSITIONS	. 03	02/334,330		
	PREPARED THEREFROM				
99-05P1	NASAL ADMINISTRATION OF	us	60/166,841	11/22/1999	
99-0311	BUTORPHANOL		00/100,041		
99-05P2	NASAL ADMINISTRATION OF	US	60/190,982	03/12/2000	
99-031 2	BUTORPHANOL	03	00/170,702		
	PHARMACEUTICAL COMPOSITIONS FOR			08/23/2000	
99-05US	NASALLY ADMINISTERED ANALGESICS	US	09/644,174		ł
	SUCH AS BUTORPHANOL				
99-06P1	METERING DEVICE	US	60/167,295	11/24/1999	
99-06US	CHILD-RESISTANT SAFETY CLOSURE	US	09/642,364	08/21/2000	
NPCI-0068	INTRANASAL FORMULATIONS FOR			09/29/1997	
719-	PROMOTING SLEEP AND METHOD OF				
6CIP/PCT/EP	USING THE SAME	Denmark	97944550.9		-
O/DENMAR		}			
K					
NPCI-0069	INTRANASAL FORMULATIONS FOR			09/29/1997	
719-	PROMOTING SLEEP AND METHOD OF	7721 d	070445500		
6CIP/PCT/EP	USING THE SAME	Finland	97944550.9		
O/FINLAND					
	USING THE SAME				

			·	
NPCI-0070	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF	France	97944550.9	
6CIP/PCT/EP	USING THE SAME	1141100	77711330.5	
O/FRANCE				
NPCI-0071	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			
6CIP/PCT/EP	USING THE SAME	United Kingdom	97944550.9	
O/GREATBR				ļ
ITAIN		i		
NPCI-0072	INTRANASAL FORMULATIONS FOR			09/29/1997
1				09/29/1997
719-	PROMOTING SLEEP AND METHOD OF		07044550.0	
6CIP/PCT/EP	USING THE SAME	Germany	97944550.9	
O/GERMAN				· · · ·
Y				
NPCI-0073	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF	Greece	97944550.9	
6CIP/PCT/EP	USING THE SAME	Greece	717 44 330.7	
O/GREECE				
NPCI-0074	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			
6CIP/PCT/EP	USING THE SAME	Ireland	97944550.9	
O/IRELAND	CONTROL TILL GRAVED			
NPCI-0075	INTRANASAL FORMULATIONS FOR			09/29/1997
ľ	PROMOTING SLEEP AND METHOD OF			09/29/1997
719-		Italy	97944550.9	
6CIP/PCT/EP	USING THE SAME			
C/ITALY				
NPCI-0076	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			
6CIP/PCT/EP	USING THE SAME	Luxembourg	97944550.9	
O/LUXEMB				
OURG				
NPCI-0077	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			
6CIP/PCT/EP	USING THE SAME	Мопосо	97944550.9	
O/MONACO	COLING TIES OF EVILE			
NPCI-0078	INTRANASAL FORMULATIONS FOR			09/29/1997
				0312311331
719-	PROMOTING SLEEP AND METHOD OF	NT-sh-sul	07044550 0	
6CIP/PCT/EP	USING THE SAME	Netherlands	97944550.9	
O/NETHERL			•	
ANDS		· .		
NPCI-0079	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			
6CIP/PCT/EP	USING THE SAME	Portugal	97944550.9	
O/PORTUGA				
L				
NPCI-0080	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF	1		
6CIP/PCT/EP	USING THE SAME	Spain	97944550.9	
O/SPAIN	COLIC TILL OVERILD			
	INTRANASAL FORMULATIONS FOR	+		09/29/1997
NPCI-0081		.		03/23/133/
719-	PROMOTING SLEEP AND METHOD OF	Sweden	97944550.9	
6CIP/PCT/EP	USING THE SAME			
O/SWEDEN			·	
OISWEDEN		<u> </u>		1

NPCI-0082	INTRANASAL FORMULATIONS FOR			09/29/1997
719-	PROMOTING SLEEP AND METHOD OF			03/23/1337
6CIP/PCT/EP	USING THE SAME	Switzerland and	97944550.9	
O/SWITZER		Liechtens	3131133013	
LAND		. [.
NPCI-0202	NASAL DELIVERY OF APOMORPHINE	-		02/18/2000
719-127		Greece	914639	02/16/2000
NPCI-0204	NASAL DELIVERY OF APOMORPHINE		6	02/18/2000
719-127	TOTAL DELIVERY OF THE OWORTHINE	Italy	914639	02/16/2000
NPCI-0205	NASAL DELIVERY OF APOMORPHINE			02/18/2000
719-127	NASAL DELIVER FOR ALOMORTHINE	Luxembourg	914639	02/18/2000
NPCI-0206	NASAL DELIVERY OF APOMORPHINE	<u> </u>	·	02/18/2000
719-127	NASAL DELIVER FOR ALOMORITHME	Monoco	914639	02/18/2000
NPCI-0207	NASAL DELIVERY OF APOMORPHINE			02/18/2000
719-127	NASAL DELIVERT OF AFOMORITHE	Netherlands	914639	02/18/2000
NPCI-0208	NASAL DELIVERY OF APOMORPHINE			02/18/2000
719-127	NASAL DELIVERT OF ATOMORITME	Portugal	914639	02/18/2000
NPCI-0209	NASAL DELIVERY OF APOMORPHINE			02/18/2000
	NASAL DELIVER I OF APOMORPHINE	Spain	914639	02/18/2000
719-127 NPCI-0210	NASAL DELIVERY OF APOMORPHINE			02/18/2000
	NASAL DELIVER I OF APOMORPHINE	Sweden	914639	02/18/2000
719-127	NASAL DELIVERY OF APOMORPHINE	Coniteration desired		00/10/0000
NPCI-0211	NASAL DELIVERY OF APOMORPHINE	Switzerland and	914639	02/18/2000
719-127	NAGAL DEL BIEDN OF A DOMODDING	Liechtens		00/10/0000
NPCI-0212	NASAL DELIVERY OF APOMORPHINE	Albania	914639	02/18/2000
719-127	NA GAL DEL WERNA OF A POLYOPPINE			
NPCI-0213	NASAL DELIVERY OF APOMORPHINE	Lithuania	914639	02/18/2000
719-127	NAME OF A POST O	-		
NPCI-0214	NASAL DELIVERY OF APOMORPHINE	Latvia	914639	02/18/2000
719-127	NA GAY DEL HEDITOE A DOLLODDY			
NPCI-0215	NASAL DELIVERY OF APOMORPHINE	Romania	914639	02/18/2000
719-127	NAME OF A POLICE PROPERTY.			
NPCI-0216	NASAL DELIVERY OF APOMORPHINE	Slovenia	914639	02/18/2000
719-127	DIVADA (A CICI WING A L FIODA (III. A ETVO) (G			0.7/20/2000
NPCI-0231	PHARMACEUTICAL FORMULATIONS	ļ l	004040	05/23/2000
719-163	AND METHODS COMPRISING	Austria	936212	
	INTRANASAL MORPHINE	<u> </u>		
NPCI-0232	PHARMACEUTICAL FORMULATIONS			05/23/2000
719-163	AND METHODS COMPRISING	Belgium	936212	1
	INTRANASAL MORPHINE			
NPCI-0233	PHARMACEUTICAL FORMULATIONS	_		05/23/2000
719-163	AND METHODS COMPRISING	Cyprus	936212	
, 15 100	INTRANASAL MORPHINE			<u> </u>
NPCI-0234	PHARMACEUTICAL FORMULATIONS			05/23/2000
719-163	AND METHODS COMPRISING	Denmark	936212	
717 105	INTRANASAL MORPHINE			
NPCI-0235	PHARMACEUTICAL FORMULATIONS			05/23/2000
719-163	AND METHODS COMPRISING	Finland	936212	
/1/103	INTRANASAL MORPHINE			
NPCI-0236	PHARMACEUTICAL FORMULATIONS			05/23/2000
719-163	AND METHODS COMPRISING	France	936212	·
715-105	INTRANASAL MORPHINE			
NPCI-0237	PHARMACEUTICAL FORMULATIONS			05/23/2000
719-163	AND METHODS COMPRISING	United Kingdom	936212	
115-103	INTRANASAL MORPHINE			

	The state of the s				Τ
NPCI-0238	PHARMACEUTICAL FORMULATIONS	_		05/23/2000	
719-163	AND METHODS COMPRISING	Germany	936212		
717-103	INTRANASAL MORPHINE			,	
NPCI-0239	PHARMACEUTICAL FORMULATIONS			05/23/2000	
	AND METHODS COMPRISING	Greece	936212		
719-163	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS		*	05/23/2000	
NPCI-0240	AND METHODS COMPRISING	Ireland	936212	03/23/2000	
719-163	INTRANASAL MORPHINE	IICIAIIG	930212		
				05/00/0000	
NPCI-0241	PHARMACEUTICAL FORMULATIONS			05/23/2000	
719-163	AND METHODS COMPRISING	Italy	936212		
717 105	INTRANASAL MORPHINE				
NPCI-0242	PHARMACEUTICAL FORMULATIONS			05/23/2000	
	AND METHODS COMPRISING	Luxembourg	936212		
719-163	INTRANASAL MORPHINE			•	
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
NPCI-0243	AND METHODS COMPRISING	Monoco	936212	00/20/2000	
719-163	INTRANASAL MORPHINE	Wichoco	930212		
	PHARMACEUTICAL FORMULATIONS			05/02/0000	
NPCI-0244			00/010	05/23/2000	
719-163	AND METHODS COMPRISING	Netherlands	936212		
	INTRANASAL MORPHINE				
NPCI-0245	PHARMACEUTICAL FORMULATIONS			05/23/2000	
719-163	AND METHODS COMPRISING	Portugal	936212		·
/19-105	INTRANASAL MORPHINE				
) TD GT 00 16	PHARMACEUTICAL FORMULATIONS			05/23/2000	
NPCI-0246	AND METHODS COMPRISING	Spain	936212		
719-163	INTRANASAL MORPHINE	J Spann	750212		-
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
NPCI-0247	AND METHODS COMPRISING	Sweden	936212	0312312000	
719-163		Sweden	930212		
	INTRANASAL MORPHINE				
NPCI-0248	PHARMACEUTICAL FORMULATIONS	Switzerland and		05/23/2000	
719-163	AND METHODS COMPRISING	Liechtens	936212		
717-105	INTRANASAL MORPHINE	Diccitons			
NPCI-0249	PHARMACEUTICAL FORMULATIONS			05/23/2000	
	AND METHODS COMPRISING	Albania	936212		
NPCI-0249	INTRANASAL MORPHINE				
	PHARMACEUTICAL FORMULATIONS		······································	05/23/2000	
NPCI-0250	AND METHODS COMPRISING	Lithuania	936212	00.20.200	
719-163	INTRANASAL MORPHINE	234444444	750212		
	PHARMACEUTICAL FORMULATIONS			05/23/2000	
NPCI-0251		.	02/010	03/23/2000	Į
719-163	AND METHODS COMPRISING	Latvia	936212		
	INTRANASAL MORPHINE		· · · · · · · · · · · · · · · · · · ·		
NPCI-0252	PHARMACEUTICAL FORMULATIONS			05/23/2000	
719-163	AND METHODS COMPRISING	Romania	936212		
/ 17-103	INTRANASAL MORPHINE				
NIDOI 0052	PHARMACEUTICAL FORMULATIONS			05/23/2000	
NPCI-0253	AND METHODS COMPRISING	Slovenia	936212		
719-163	INTRANASAL MORPHINE				
NPCI-0281	STA-T Trademark			04/14/2000	
719-185	OTT T TIMOUTHER	US	76/025,952	V-17 1-77 2000	
NPCI-	STA-T Trademark	 		12/21/2001	
	SIA-1 Hademark	110	01150007	12/21/2001	
0281TTAB		US	91150896		
719-185	1				

NPCI-	STA-T Trademark		,	12/21/2001	
0281TTAB1		US	91150896		
719-185					

PATENT REEL: 023973 FRAME: 0352

RECORDED: 02/23/2010